ORIGINAL_ARTICLE
The worldwide frequency of MYO15A gene mutations in patients with autosomal recessive non-syndromic hearing loss: A meta‐analysis
MYO15A is the third most crucial gene in hereditary sensorineural hearing loss after GJB2 and SLC26A4. In the present study, we reviewed the prevalence of MYO15A mutations in patients with autosomal recessive non-syndromic hearing loss (ARNSHL). In this meta-analysis, we conducted a search of PubMed, Web of Science, Excerpta Medica Database, and Scopus, and identified the articles up to September 2019 without any time limit. Two investigators independently selected the relevant papers and extracted the required information. A total of 44 case-control and case series studies were considered, and 4176 patients and 3706 healthy individuals, as the control group, were included. The pooled frequency of MYO15A mutations between patients suffering from ARNSHL was calculated as 6.2% (95% CI: 4.9-7.8, P-value<0.001). There was heterogeneity between our studies (P-value<0.001, I2=58.1%); therefore, the random-effects model was utilized for analysis. Given the results, in many countries, the MYO15A gene had a significant contribution to hearing loss. Moreover, in several regions, specific dominant mutations in this gene have been reported. Therefore, the ethnic background should be considered to investigate the mutations of the MYO15A gene.
https://ijbms.mums.ac.ir/article_15655_57e2e4a2ae3f2d97d5498723ad6da6b4.pdf
2020-07-01
841
848
10.22038/ijbms.2020.35977.8563
autosomal recessive
Deafness
Meta-analysis
Mutation
MYO15A
Non-syndromic hearing loss
Prevalence
Mahsa
Farjami
farjamim941@mums.ac.ir
1
Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Reza
Asadi
asadir@mums.ac.ir
2
Department of Education Development Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Fahimeh
Afzal Javan
afzaljf911@mums.ac.ir
3
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Malihe
Alimardani
alimardanim942@mums.ac.ir
4
Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Saeed
Eslami
eslamis@mums.ac.ir
5
Pharmaceutical Research Center, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Sima
Mansoori Derakhshan
mderakhshan2002@gmail.com
6
Department of Medical Genetics, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Atieh
Eslahi
eslahia951@mums.ac.ir
7
Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Majid
Mojarad
mojaradm@mums.ac.ir
8
Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Atik T, Onay H, Aykut A, Bademci G, Kirazli T, Tekin M, et al. Comprehensive analysis of deafness genes in families with autosomal recessive nonsyndromic hearing loss. PLoS One 2015; 10-21.
1
2. Yan D, Tekin D, Bademci G, Foster J, 2nd, Cengiz FB, Kannan-Sundhari A, et al. Spectrum of DNA variants for non-syndromic deafness in a large cohort from multiple continents. Hum Genet 2016; 135:953-961.
2
3. Mahdieh N, Rabbani B, Wiley S, Akbari MT, Zeinali S. Genetic causes of nonsyndromic hearing loss in Iran in comparison with other populations. J Hum Genet 2010; 55:639-648.
3
4. Miyagawa M, Nishio SY, Hattori M, Moteki H, Kobayashi Y, Sato H, et al. Mutations in the MYO15A gene are a significant cause of nonsyndromic hearing loss: Massively parallel DNA sequencing-based analysis. Ann Otol Rhinol Laryngol 2015; 124:158S-168S.
4
5. Rabbani B, Tekin M, Mahdieh N. The promise of whole-exome sequencing in medical genetics. J Hum Genet 2014; 59:5-15.
5
6. Hofrichter MAH, Mojarad M, Doll J, Grimm C, Eslahi A, Hosseini NS, et al. The conserved p.Arg108 residue in S1PR2 (DFNB68) is fundamental for proper hearing: Evidence from a consanguineous Iranian family. BMC Med Genet 2018; 19:81-91.
6
7. Alimardani M, Hosseini SM, Khaniani MS, Haghi MR, Eslahi A, Farjami M, et al. Targeted mutation analysis of the SLC26A4, MYO6, PJVK and CDH23 genes in Iranian patients with AR nonsyndromic hearing loss. Fetal Pediatr Pathol 2019; 38:93-102.
7
8. Yan D, Tekin D, Bademci G, Foster J, Cengiz FB, Kannan-Sundhari A, et al. Spectrum of DNA variants for non-syndromic deafness in a large cohort from multiple continents. Hum Genet 2016; 135:953-961.
8
9. Masoudi M, Ahangari N, Zonouzi AAP, Zonouzi AP, Nejatizadeh A. Genetic linkage analysis of DFNB3, DFNB9 and DFNB21 loci in GJB2 negative families with autosomal recessive non-syndromic hearing loss. Iran J Public Health 2016; 45:680-687.
9
10. Palombo F, Al-Wardy N, Ruscone GAG, Oppo M, Al Kindi MN, Angius A, et al. A novel founder MYO15A frameshift duplication is the major cause of genetic hearing loss in Oman. J Hum Genet 2017; 62:259-264.
10
11. Rehman AU, Bird JE, Faridi R, Shahzad M, Shah S, Lee K, et al. Mutational spectrum of MYO15A and the molecular mechanisms of DFNB3 human deafness. Hum Mutat 2016; 37:991-1003.
11
12. Reiisi S, Tabatabaiefar MA, Sanati MH, Chaleshtori MH. Screening of DFNB3 in Iranian families with autosomal recessive non-syndromic hearing loss reveals a novel pathogenic mutation in the MyTh4 domain of the MYO15A gene in a linked family. Iran J Basic Med Sci 2016; 19:772-778.
12
13. Shearer AE, Hildebrand MS, Webster JA, Kahrizi K, Meyer NC, Jalalvand K, et al. Mutations in the first MyTH4 domain of MY015A are a common cause of DFNB3 hearing loss. Laryngoscope 2009; 119:727-733.
13
14. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012; 65:934-939.
14
15. Subaşıoğlu A. Research of genetic bases of hereditary non-syndromic hearing loss. Turk Pediatri Ars;122-133.
15
16. Tabatabaiefar M, Alasti F, Zohour MM, Shariati L, Farrokhi E, Farhud D, et al. Genetic linkage analysis of 15 DFNB loci in a group of Iranian families with autosomal recessive hearing loss. Iran J Public Health 2011; 40:34-48.
16
17. Miyagawa M, Nishio Sy, Ikeda T, Fukushima K, Usami Si. Massively parallel DNA sequencing successfully identifies new causative mutations in deafness genes in patients with cochlear implantation and EAS. PLoS One 2013; 8:e75793.
17
18. Manzoli GN, Bademci G, Acosta AX, Felix TM, Cengiz FB, Foster J, et al. Targeted resequencing of deafness genes reveals a founder MYO15A variant in northeastern Brazil. Ann Hum Genet 2016; 80:327-331.
18
19. Tsukada K, Nishio Sy, Hattori M, Usami Si. Ethnic-specific spectrum of GJB2 and SLC26A4 mutations: Their origin and a literature review. Ann Otol Rhinol Laryngol 2015; 124:61S-76S.
19
20. http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MYO15A
20
21. Yan D, Kannan-Sundhari A, Vishwanath S, Qing J, Mittal R, Kameswaran M, et al. The genetic basis of nonsyndromic hearing loss in Indian and Pakistani populations. Genet Test Mol Biomarkers 2015; 19:512-527.
21
22. Sommen M, Schrauwen I, Vandeweyer G, Boeckx N, Corneveaux JJ, van den Ende J, et al. DNA diagnostics of hereditary hearing loss: A targeted resequencing approach combined with a mutation classification system. Hum Mutat 2016; 37:812-819.
22
23. Brownstein Z, Friedman LM, Shahin H, Oron-Karni V, Kol N, Abu Rayyan A, et al. Targeted genomic capture and massively parallel sequencing to identify genes for hereditary hearing loss in Middle Eastern families. Genome Biol 2011; 12:R89.
23
24. Yang T, Wei X, Chai Y, Li L, Wu H. Genetic etiology study of the non-syndromic deafness in Chinese Hans by targeted next-generation sequencing. Orphanet J Rare Dis 2013; 8:85-93.
24
25. Nal N, Ahmed ZM, Erkal E, Alper ÖM, Lüleci G, Dinç O, et al. Mutational spectrum of MYO15A: The large N-terminal extension of myosin XVA is required for hearing. Hum Mutat 2007; 28:1014-1019.
25
26. Miyagawa M, Naito T, Nishio SY, Kamatani N, Usami S. Targeted exon sequencing successfully discovers rare causative genes and clarifies the molecular epidemiology of Japanese deafness patients. PLoS One 2013; 8:e71381.
26
27. Cengiz FB, Duman D, Sirmaci A, Tokgöz-Yilmaz S, Erbek S, Öztürkmen-Akay H, et al. Recurrent and private MYO15A mutations are associated with deafness in the Turkish population. Genet Test Mol Biomarkers 2010; 14:543-550.
27
28. Palombo F, Al-Wardy N, Ruscone GA, Oppo M, Kindi MN, Angius A, et al. A novel founder MYO15A frameshift duplication is the major cause of genetic hearing loss in Oman. J Hum Genet 2017; 62:259-264.
28
29. Sloan-Heggen CM, Babanejad M, Beheshtian M, Simpson AC, Booth KT, Ardalani F, et al. Characterising the spectrum of autosomal recessive hereditary hearing loss in Iran. J Med Genet 2015; 52:823-829.
29
30. Duman D, Sirmaci A, Cengiz FB, Ozdag H, Tekin M. Screening of 38 genes identifies mutations in 62% of families with nonsyndromic deafness in Turkey. Genet Test Mol Biomarkers 2011; 15:29-33.
30
31. Cengiz FB, Duman D, Sirmaci A, Tokgoz-Yilmaz S, Erbek S, Ozturkmen-Akay H, et al. Recurrent and private MYO15A mutations are associated with deafness in the Turkish population. Genet Test Mol Biomarkers 2010; 14:543-550.
31
32. Naz S, Imtiaz A, Mujtaba G, Maqsood A, Bashir R, Bukhari I, et al. Genetic causes of moderate to severe hearing loss point to modifiers. Clin Genet 2017; 91:589-598.
32
33. Bashir R, Fatima A, Naz S. Prioritized sequencing of the second exon of MYO15A reveals a new mutation segregating in a Pakistani family with moderate to severe hearing loss. Eur J Med Genet 2012; 55:99-102.
33
34. Liburd N, Ghosh M, Riazuddin S, Naz S, Khan S, Ahmed Z, et al. Novel mutations of MYO15A associated with profound deafness in consanguineous families and moderately severe hearing loss in a patient with Smith-Magenis syndrome. Hum Genet 2001; 109:535-541.
34
35. Kalay E, Uzumcu A, Krieger E, Caylan R, Uyguner O, Ulubil-Emiroglu M, et al. MY015A (DFNB3) mutations in Turkish hearing loss families and functional modeling of a novel motor domain mutation. Am J Med Genet A 2007; 143A:2382-2389.
35
36. Sadeghi A, Sanati MH, Alasti F, Chaleshtori MH, Mahmoudian S, Ataei M. Contribution of GJB2 mutations and Four common DFNB loci in autosomal recessive non-syndromic hearing impairment in Markazi and Qom provinces of Iran. Iran J Biotechnol 2009; 7:108-111+120.
36
37. Belguith H, Aifa-Hmani M, Dhouib H, Said MB, Mosrati MA, Lahmar I, et al. Screening of the DFNB3 locus: identification of three novel mutations of MYO15A associated with hearing loss and further suggestion for two distinctive genes on this locus. Genet Test Mol Biomarkers 2009; 13:147-151.
37
38. Shahin H, Walsh T, Abu Rayyan A, Lee MK, Higgins J, Dickel D, et al. Five novel loci for inherited hearing loss mapped by SNP-based homozygosity profiles in Palestinian families. Eur J Hum Genet 2010; 18:407-413.
38
39. Diaz-Horta O, Duman D, Foster J, 2nd, Sirmaci A, Gonzalez M, Mahdieh N, et al. Whole-exome sequencing efficiently detects rare mutations in autosomal recessive nonsyndromic hearing loss. PLoS One 2012; 7:e50628.
39
40. Fattahi Z, Shearer AE, Babanejad M, Bazazzadegan N, Almadani SN, Nikzat N, et al. Screening for MYO15A gene mutations in autosomal recessive nonsyndromic, GJB2 negative Iranian deaf population. Am J Med Genet A 2012; 158A:1857-1864.
40
41. Woo HM, Park HJ, Baek JI, Park MH, Kim UK, Sagong B, et al. Whole-exome sequencing identifies MYO15A mutations as a cause of autosomal recessive nonsyndromic hearing loss in Korean families. BMC Med Genet 2013; 14:72.
41
42. Brownstein Z, Abu-Rayyan A, Karfunkel-Doron D, Sirigu S, Davidov B, Shohat M, et al. Novel myosin mutations for hereditary hearing loss revealed by targeted genomic capture and massively parallel sequencing. Eur J Hum Genet 2014; 22:768-775.
42
43. Shafique S, Siddiqi S, Schraders M, Oostrik J, Ayub H, Bilal A, et al. Genetic spectrum of autosomal recessive non-syndromic hearing loss in Pakistani families. PLoS One 2014; 9-19.
43
44. Vona B, Müller T, Nanda I, Neuner C, Hofrichter MAH, Schröder J, et al. Targeted next-generation sequencing of deafness genes in hearing-impaired individuals uncovers informative mutations. Genet Med 2014; 16:945-953.
44
45. Atik T, Onay H, Aykut A, Bademci G, Kirazli T, Tekin M, et al. Comprehensive analysis of deafness genes in families with autosomal recessive nonsyndromic hearing Loss. PLoS One 2015; 10:e0142154.
45
46. Gu X, Guo L, Ji H, Sun S, Chai R, Wang L, et al. Genetic testing for sporadic hearing loss using targeted massively parallel sequencing identifies 10 novel mutations. Clin Genet 2015; 87:588-593.
46
47. Ammar‐Khodja F, Bonnet C, Dahmani M, Ouhab S, Lefèvre GM, Ibrahim H, et al. Diversity of the causal genes in hearing impaired Algerian individuals identified by whole exome sequencing. Mol Genet Genomic Med 2015; 3:189-196.
47
48. Asgharzade S, Chaleshtori MH, Tabatabaifar MA, Reisi S, Modaressi MH. Mutation in second exon of myo15a gene cause of nonsyndromic hearing loss and its association in the Arab population in Iran. Genetika 2016; 48:587-596.
48
49. Moteki H, Azaiez H, Booth KT, Shearer AE, Sloan CM, Kolbe DL, et al. Comprehensive genetic testing with ethnic‐specific filtering by allele frequency in a Japanese hearing‐loss population. Clin Genet 2016; 89:466-472.
49
50. Jung J, Lee JS, Cho KJ, Yu S, Yoon JH, Gee HY, et al. Genetic predisposition to sporadic congenital hearing loss in a pediatric population. Sci Rep 2017; 7-16.
50
51. Salime S, Charif M, Bousfiha A, Elrharchi S, Bakhchane A, Charoute H, et al. Homozygous mutations in PJVK and MYO15A genes associated with non-syndromic hearing loss in Moroccan families. Int J Pediatr Otorhinolaryngol 2017; 101:25-29.
51
52. Baux D, Vaché C, Blanchet C, Willems M, Baudoin C, Moclyn M, et al. Combined genetic approaches yield a 48% diagnostic rate in a large cohort of French hearing-impaired patients. Sci Rep 2017; 7:16783-16793.
52
53. Cabanillas R, Dineiro M, Cifuentes GA, Castillo D, Pruneda PC, Alvarez R, et al. Comprehensive genomic diagnosis of non-syndromic and syndromic hereditary hearing loss in Spanish patients. BMC Med Genomics 2018; 11-28.
53
54. Chen Y, Lu Y, Kuyaxi P, Cheng J, Zhao J, Zhao Q, et al. Identification of pathogenic genes of nonsyndromic hearing loss in Uyghur families using massively parallel DNA sequencing technique. Dis Markers 2018.
54
55. Danial-Farran N, Brownstein Z, Gulsuner S, Tammer L, Khayat M, Aleme O, et al. Genetics of hearing loss in the Arab population of Northern Israel. Eur J Hum Genet 2018; 26:1840-1847.
55
56. Guan Q, Balciuniene J, Cao K, Fan Z, Biswas S, Wilkens A, et al. AUDIOME: a tiered exome sequencing–based comprehensive gene panel for the diagnosis of heterogeneous nonsyndromic sensorineural hearing loss. Genet Med 2018; 20:1600-1608.
56
57. He L, Pang X, Liu H, Chai Y, Wu H, Yang T. Targeted next-generation sequencing and parental genotyping in sporadic Chinese Han deaf patients. Clin Genet 2018; 93:899-904.
57
58. Han JJ, Nguyen PD, Oh DY, Han JH, Kim AR, Kim MY, et al. Elucidation of the unique mutation spectrum of severe hearing loss in a Vietnamese pediatric population. Sci Rep 2019; 9-18.
58
59. Khan A, Han S, Wang R, Ansar M, Ahmad W, Zhang X. Sequence variants in genes causing nonsyndromic hearing loss in a Pakistani cohort. Mol Genet Genomic Med 2019:e917.
59
60. Liu WH, Chang PY, Chang SC, Lu JJ, Wu CM. Mutation screening in non-syndromic hearing loss patients with cochlear implantation by massive parallel sequencing in Taiwan. PLoS One 2019; 14-29.
60
61. Mehregan H, Mohseni M, Jalalvand K, Arzhangi S, Nikzat N, Banihashemi S, et al. Novel mutations in MYTH4-FERM domains of myosin 15 are associated with autosomal recessive nonsyndromic hearing loss. Int J Pediatr Otorhinolaryngol 2019; 117:115-126.
61
62. Sang SS, Ling J, Liu XZ, Mei LY, Cai XZ, Li TX, et al. Proband whole-exome sequencing identified genes responsible for autosomal recessive non-syndromic hearing loss in 33 Chinese nuclear families. Front Genet 2019; 10-20.
62
ORIGINAL_ARTICLE
Thymoquinone: From Nigella sativa to a protective pharmacological compound in managing opioid dependence and amphetamine type stimulant issues
Opioids, amphetamines, and other types of substances have been widely abused around the world. Opioid dependence and tolerance are two distinct phenomena that have been associated with substance abuse issues. The management of its adverse consequences is becoming more challenging. More and more people are treated in Methadone Maintenance Therapy (MMT) program yet the issues are still unresolved. Researchers are continuing to study the best formulation in treating opioid dependent people starting with modern and alternative drug therapies. Since 2008 , thymoquinone (TQ) has been extensively studied by researchers around the world and has emerged to be a new potential drug candidate in managing substance abuse issues. Thus, the aim of this article is to review the effects that TQ may have on opioid dependent subjects and other abused substances such as amphetamine may have been studied. All of the articles from 2008 until 2019 involving the effects of TQ on substance abuse from Google Scholar®, Scopus®, and Pubmed® databases have been searched and reviewed. The keywords used were thymoquinone, opioid dependence, amphetamine, and Nigella sativa. The research results also have been discussed in this article. Based on the research conducted, TQ was effective in reducing the adverse health consequences associated with substance abuse such as withdrawal symptoms, tolerance, and cell damages. It is concluded that TQ could be a potential drug that can be complemented with the currently available drugs in substance abuse therapies.
https://ijbms.mums.ac.ir/article_15570_17f6727fc14e27c5ed758c96e3b8c3cc.pdf
2020-07-01
849
852
10.22038/ijbms.2020.41678.9841
Amphetamine
methadone
Morphine toxicity
Opioid dependence syndromes
Thymoquinone
Liyana Hazwani
Mohd Adnan
liyanahazwani@unisza.edu.my
1
Faculty of Medicine, University Sultan Zainal Abidin, City Campus, 20400 Kuala Terengganu, Malaysia
LEAD_AUTHOR
Nor Hidayah
Abu Bakar
norhidayahabubakar@unisza.edu.my
2
Faculty of Medicine, University Sultan Zainal Abidin, City Campus, 20400 Kuala Terengganu, Malaysia
AUTHOR
Nordin
Simbak
nordinsimbak@unisza.edu.my
3
Faculty of Medicine, University Sultan Zainal Abidin, City Campus, 20400 Kuala Terengganu, Malaysia
AUTHOR
Nasir
Mohamad
nasirmohamad@unisza.edu.my
4
Faculty of Medicine, University Sultan Zainal Abidin, City Campus, 20400 Kuala Terengganu, Malaysia
AUTHOR
Rusli
Ismail
isrusli@unisza.edu.my
5
Faculty of Medicine, University Sultan Zainal Abidin, City Campus, 20400 Kuala Terengganu, Malaysia
AUTHOR
Nor Zidah
Ahmad
zieta_ieda@yahoo.com.my
6
Faculty of Medicine, University Sultan Zainal Abidin, City Campus, 20400 Kuala Terengganu, Malaysia
AUTHOR
Nor Suliana
Mustafa
norsulianamustafa@gmail.com
7
Faculty of Medicine, University Sultan Zainal Abidin, City Campus, 20400 Kuala Terengganu, Malaysia
AUTHOR
Nurul Farah Aina
Md Fauzi
nurulfaina92@gmail.com
8
Faculty of Medicine, University Sultan Zainal Abidin, City Campus, 20400 Kuala Terengganu, Malaysia
AUTHOR
1. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009; 10:1727-1740.
1
2. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2004; 11:44-49.
2
3. Ghayur MN, Gilani AH, Janssen LJ. Intestinal, airway, and cardiovascular relaxant activities of thymoquinone. Evid Based Complement Alternat Med 2012; 2012:1-13.
3
4. Nutten S, Philippe D, Mercenier A, Duncker. Opioid receptors stimulating compounds (thymoquinone, nigella sativa) and food allergy: United states patent application no. 13/321,060.
4
5. Ahmad NZ, Mat KC, Mohamad N, Husain RB, Bakar NH, Zakaria NH, et al. A review on opioid dependence, mechanism and treatments used: option of treatments: modern versus alternative medicine. Bangladesh J Med Sci 2019; 18:171-177.
5
6. Shahraki S, Khajavirad A, Shafei MN, Mahmoudi M, Tabasi NS. Effect of total hydroalcholic extract of Nigella sativa and its n-hexane and ethyl acetate fractions on ACHN and GP-293 cell lines. J Tradit Complement Med 2015; 6:89-96.
6
7. Mehri S, Shahi M, Razavi BM, Hassani FV, Hosseinzadeh H. Neuroprotective effect of thymoquinone in acrylamide-induced neurotoxicity in Wistar rats. Iran J Basic Med Sci 2014; 17:1007-1011.
7
8. Sangi S, Ahmed SP, Channa MA, Ashfaq M, Mastoi SM. A new and novel treatment of opioid dependence: Nigella sativa 500 mg. J Ayub Med Coll Abbottabad 2008; 20:118-124.
8
9. Linjawi SA, Khalil WK, Hassanane MM, Ahmed ES. Evaluation of the protective effect of Nigella sativa extract and its primary active component thymoquinone against DMBA-induced breast cancer in female rats. Arch Med Sci 2015; 11:220-229.
9
10. Hosseinzadeh H, Parvardeh S, Nassiri-Asl M, Mansouri MT. Intracerebroventricular administration of thymoquinone, the major constituent of Nigella sativa seeds, suppresses epileptic seizures in rats. Med Sci Monit 2005; 11: 106-110.
10
11. Javidi S, Razavi BM, Hosseinzadeh H. A review of neuropharmacology effects of Nigella sativa and its main component, thymoquinone. Phytother Res 2016; 30:1219-1229.
11
12. Abdel-Zaher AO, Mostafa MG, Farghly HM, Hamdy MM, Omran GA, Al-Shaibani NK. Inhibition of brain oxidative stress and inducible nitric oxide synthase expression by thymoquinone attenuates the development of morphine tolerance and dependence in mice. Eur J Pharmacol 2013; 702:62-70.
12
13. Tabatabai SM, Dashti S, Doosti F, Hosseinzadeh H. Phytotherapy of opioid dependence and withdrawal syndrome: a review. Phytother Res 2014; 28:811-830.
13
14. Mohamad N, Bakar N, Musa N, Talib N, Ismail R. Better retention of Malaysian opiate dependents treated with high dose methadone in methadone maintenance therapy. Harm Reduct J 2010; 7:30-38.
14
15. Zhang L, Chow EP, Zhuang X, Liang Y, Wang Y, Tang C, et al. Methadone maintenance treatment participant retention and behavioural effectiveness in China: a systematic review and meta-analysis. Plos One 2013; 8:68906-68916.
15
16. Yang F, Lin P, Li Y, He Q, Long Q, Fu X, et al. Predictors of retention in community-based methadone maintenance treatment program in Pearl River Delta, China. Harm Reduct J 2013;10:3-10.
16
17. Adnan LMA, Mohamad N, Bakar NHA. Opioid dependent and substitution therapy: thymoquinone as potential novel supplement therapy for better outcome for mmt substitution therapy. Iran J Basic Med Sci 2014; 17:926-928.
17
18. Hosseinzadeh H, Parvardeh S, Masoudi A, Moghimi M, Mahboobifard F. Attenuation of morphine tolerance and dependence by thymoquinone in mice. Avicenna J Phytomed 2016; 6:55-66.
18
19. Adnan LHM, Mohamad N, Mat KC, Yeo CC, Bakar NH, Ismail R. Thymoquinone regulates gene expression levels in morphine addiction pathways in opioid receptor expressing cells (U87 MG). Electronic J Biol 2017; 13:166-173.
19
20. Liyana HMA, Nasir M, Khairi CM, Nor Hidayah AB, Siti NH, Mohd HM et al. Attenuation of morphine-induced cAMP overshoot by thymoquinone in opioid receptor expressing cells (u87 mg) mediated by chronic morphine treatment. J Eng Appl Sci 2018; 13:8906-8911.
20
21. Nestler EJ. Molecular mechanisms of drug addiction. Neuropharmacology 2004; 47:24-32.
21
22. Jalili C, Sohrabi M, Jalili F, Salahshoor MR. Assessment of thymoquinone effects on apoptotic and oxidative damage induced by morphine in mice heart. Cell Mol Biol 2018; 64:33-38.
22
23. Jalili C, Salahshoor MR, Hoseini M, Roshankhah S, Sohrabi M, Shabanizadeh A. Protective effect of thymoquinone against morphine injuries to kidneys of mice. Iran J Kidney Dis 2017; 11:142-150.
23
24. Md Fauzi NF, Bakar NH, Mohamad N, Mat KC, Omar SH, Othman M, et al. Potential therapeutic effects of thymoquinone on treatment of amphetamine abuse. Asian Pac J Trop Biomed 2018; 8:187-188.
24
25. Schrantee A, Vaclav L, Heijtel DF, Caan MWA, Gsell W, Lucassen PJ, et al. Dopaminergic system dysfunction in recreational dexamphetamine users. Neuropsychopharmacol 2015; 40:1172-1180.
25
26. Ciccarone D. Stimulant abuse: Pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care 2011; 38:41-58.
26
27. Norliza C, Norni A, Anandjit S, Mohd FM. A review of substance abuse research in Malaysia. Med Journal Malays 2014; 69:55-58.
27
28. Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: A systematic review and meta-analysis. JAMA Psychiatry 2017; 74:511-519.
28
29. Mustafa NS, Bakar NH, Adnan LH, Fauzi NF, Thoarlim A, Omar SH, et al. Protective effects of thymoquinone on the MDMA-induced cerebrospinal fluid serotonin depletion in rats. Transylv Rev 2018; 1:1.
29
ORIGINAL_ARTICLE
Evaluation of CD133 and CD56/NCAM expression in Wilms tumor and their association with prognostic factors
Objective(s): To validate certain markers for cancer stem cell populations and their clinical importance in Wilms tumor (WT)Materials and Methods: Immunohistochemical study for CD133 and CD56/NCAM was performed on forty-six cases of WT that were diagnosed between 1999 and 2015, and the association of these markers with survival and prognostic factors was analyzed. Results: Thirty-four (73.9%) of WTs were positive for CD133 and thirty-nine (84.8%) were positive for CD56/NCAM. A significant positive correlation between CD133 and CD56/NCAM expression and the National Wilms Tumor Stage (NWTS) and death was found. Moreover, overall survival time was significantly correlated with CD133 and CD56/NCAM H-score, NWTS stage, and death. Conclusion: It seems that CD133 and CD56/NCAM expressions can be used as strong prognostic parameters for the survival of patients with WT and can be used to predict WT patients’ stage. Moreover, their targeted therapies can abolish cancer stem cells in children with recurrent tumors.
https://ijbms.mums.ac.ir/article_15595_f23caf5c20bf2ab1439466f23133c28c.pdf
2020-07-01
853
857
10.22038/ijbms.2020.41468.9804
CD133
immunohistochemistry
Neural cell adhesion molecules
Stem cells
Wilms tumor
Amir Hossein
Jafarian
jafarianah@mums.ac.ir
1
Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Nona
Zaboli Nejad
zabolinejadn@mums.ac.ir
2
Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Nema
Mohamadian Roshan
roshann@mums.ac.ir
3
Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Sara
Hashemi
hashemi1979@gmail.com
4
Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Masoumeh
Gharib
gharibm@mums.ac.ir
5
Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Rich JN. Cancer stem cells: understanding tumor hierarchy and heterogeneity. Medicine 2016;95(Suppl).
1
2. Pode‐Shakked N, Shukrun R, Mark‐Danieli M, Tsvetkov P, Bahar S, Pri‐Chen S, et al. The isolation and characterization of renal cancer initiating cells from human Wilms’ tumour xenografts unveils new therapeutic targets. EMBO Mol Med 2013;5:18-37.
2
3. Sternberg’s diagnostic surgical pathology. 6th ed Philadelphia: Wolters Kluwer, 2015.
3
4. Stocker J. Pediatric pathology: Wolters Kluwer Health 2010.
4
5. Ali A, Diaz R, Shu H, Paulino A, Esiashvili N. A Surveillance, Epidemiology and End Results (SEER) program comparison of adult and pediatric Wilms’ tumor. Cancer 2012;118:2541-2551.
5
6. Zhang H, Li S. Research progression of CD133 as a marker of cancer stem cells. Chin J Cancer 2010;29:243-247.
6
7. Friedman G, Yancey Gillespie G. Cancer stem cells and pediatric solid tumors. Cancers 2011;3:298-318.
7
8. Kim K, Ihm H, Ro J, Cho Y. High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis. Oncol Lett 2011;2:1095-1100.
8
9. Brugnoli F, Grassilli S, Al-Qassab Y, Capitani S, Bertagnolo V. CD133 in breast cancer cells: more than a stem cell marker. J Oncol 2019;2019:7512632.
9
10. Salnikov A, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non‐small cell lung cancer patients. Int J Cancer 2010;126:950-895.
10
11. Yap LW, Brok J, Pritchard-Jones K. Role of CD56 in normal kidney development and Wilms tumorigenesis. Fetal Pediatr Pathol 2017; 36:62-75.
11
12. Jafarian AH, Gharib M, Roshan NM, Sherafatnia S, Omidi AA, Bagheri S. The diagnostic value of TTF-1, P63, HMWK, CK7, and CD56 immunostaining in the classification of lung Carcinoma. Iran J Pathol 2017;12:195-201.
12
13. Lambert J, O’Leary J, Whiteman K, Goldmacher V. Targeting CD56 (CD56/NCAM)-Expressing Neoplasms with Lorvotuzumab Mertansine. Antibody-Drug Conjugates and Immunotoxins: Springer 2013. p. 273-293.
13
14. Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N. Harnessing the immune system against leukemia: monoclonal antibodies and checkpoint strategies for AML. Adv Exp Med Biol 2017;995:73-95.
14
15. Mehrazma M, Madjd Z, Kalantari E, Panahi M, Hendi A, Shariftabrizi A. Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray. Fetal Pediatr Pathol 2013;32:192-204.
15
16. Rosai J, Ackerman L. surgical pathology: Elsevier 2018.
16
17. Ehrlich P, Ritchey M, Hamilton T, Haase G, Ou S, Breslow N, et al. Quality assessment for Wilms’ tumor: a report from the National Wilms’ Tumor Study-5. J Pediatr Surg 2005;40:208-213.
17
18. Pradhan T, Padmanabhan K, Prasad M, Chandramohan K, Nair SA. Augmented CD133 expression in distal margin correlates with poor prognosis in colorectal cancer. J Cell Mol Med 2019;23:3984-3994.
18
19. Yu GF, Lin X, Luo RC, Fang WY. Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma. Int J Cli Exp Pathol 2018;11:2092-2099.
19
20. Zhong ZY, Shi BJ, Zhou H, Wang WB. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma. J Int Med Res 2018;46:1209-1220.
20
21. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke B, Becker N, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008;14:123-129.
21
22. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009;15:2258-2264.
22
23. Ash S, Luria D, Cohen I, Goshen Y, Toledano H, Issakov J, et al. Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry. Clin Cancer Res 2011;17:2900-2907.
23
24. Tsuchiya A, Kamimura H, Tamura Y, Takamura M, Yamagiwa S, Suda T, et al. Hepatocellular carcinoma with progenitor cell features distinguishable by the hepatic stem/progenitor cell marker CD56/NCAM. Cancer Lett 2011;309:95-103.
24
ORIGINAL_ARTICLE
Involvement of the 5-HT1A receptor of the cuneiform nucleus in the regulation of cardiovascular responses during normal and hemorrhagic conditions
Objective(s): The 5-hydroxytryptamine1A (5-HT1A) receptor is one of the serotonin receptors in the brain, which regulates cardiovascular responses, especially in hemorrhage. Presence of this receptor in the cuneiform nucleus (CnF) has been shown. The present study evaluates the cardiovascular effect of this receptor of the CnF in normal and hypotensive hemorrhagic rats.Materials and Methods: Agonist (8-OH-DPAT) and antagonist (WAY-100635) of 5-HT1A microinjected into the CnF in basal and hemorrhagic conditions and cardiovascular responses were evaluated. Hemorrhage induced by blood withdrawal from the femoral artery and 2 min after that drugs microinjected. Time course and peak changes (∆) of the mean arterial pressure (MAP), systolic blood pressure (SBP) and heart rate (∆HR) were obtained and compared to the control and hemorrhage groups.Results: In basal condition, 8-OH-DPAT significantly decreased ∆SBP, ∆MAP and ∆HR compared to the control (P<0.05-P<0.01), while way-100635 did not have a significant effect. Hypotension and tachycardia induced by hemorrhage ameliorated by agonist (P<0.05-P<0.01), while antagonist deteriorated hypotension (P<0.05) but attenuated tachycardia (P<0.01).Conclusion: This study shows that 5-HT1A receptor of the CnF involves in regulation of the cardiovascular responses. However, this effect in basal and hemorrhage conditions is different.
https://ijbms.mums.ac.ir/article_15504_3ef653f551a06a866c9e46dcaa1e707d.pdf
2020-07-01
858
864
10.22038/ijbms.2020.40453.9579
Hemorrhage
Mean arterial pressure
Medullary nucleus
Serotonin receptor
Systolic blood pressure
Reza
Mohebbati
mohebbatir931@mums.ac.ir
1
Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mahmoud
Hosseini
mhosseini@mums.ac.ir
2
Division of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Majid
Khazaei
khazaeim@mums.ac.ir
3
Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Abolfazl
Khajavirad
khajavirada@mums.ac.ir
4
Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mohammad Naser
Shafei
shafeimn@mums.ac.ir
5
Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Ramage AG, Villalón CM. 5-hydroxytryptamine and cardiovascular regulation. Trend Pharmacol Sci 2008; 29:472-481.
1
2. Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev 2012; 64:359-388.
2
3. Mohammad‐Zadeh L, Moses L, Gwaltney‐Brant S. Serotonin: a review. J Vet Pharmacol Ther 2008; 31:187-199.
3
4. Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 1994; 74:323-364.
4
5. McCALL RB, Clement ME. Role of serotonin1A and serotonin2 receptors in the central regulation of the cardiovascular system. Pharmacol Rev 1994; 46:231-243.
5
6. Scrogin KE, Johnson AK, Brooks VL. Methysergide delays the decompensatory responses to severe hemorrhage by activating 5-HT1A receptors. Am J Physiol Regul Integ Comparat Physiol 2000; 279:1776-1786.
6
7. Dean C, Bago M. Renal sympathoinhibition mediated by 5-HT1Areceptors in the RVLM during severe hemorrhage in rats. Am J Physiol Regul Integ Comparat Physiol 2002; 282:122-130.
7
8. Bago M, Dean C. Sympathoinhibition from ventrolateral periaqueductal gray mediated by 5-HT1A receptors in the RVLM. Am J Physiol Regul Integ Comparat Physiol 2001; 280:976-984.
8
9. Gioia M, Bianchi R. The cytoarchitecture of the nucleus cuneiformis. A Nissl and Golgi study. J Anat 1987; 155:165-176.
9
10. Lam W, Gundlach AL, Verberne AJ. Increased nerve growth factor inducible-A gene and c-fos messenger RNA levels in the rat midbrain and hindbrain associated with the cardiovascular response to electrical stimulation of the mesencephalic cuneiform nucleus. Neurosci 1996; 71:193-211.
10
11. Allen LF, Inglis WL, Winn P. Is the cuneiform nucleus a critical component of the mesencephalic locomotor region? An examination of the effects of excitotoxic lesions of the cuneiform nucleus on spontaneous and nucleus accumbens induced locomotion. Brain Res Bull 1996; 41:201-210.
11
12. Verberne AJ, Lam W, Owens NC, Sartor D. Supramedullary modulation of sympathetic vasomotor function. Clin Exp Pharmacol Physiol 1997; 24:748-754.
12
13. Pose I, Sampogna S, Chase MH, Morales FR. Cuneiform neurons activated during cholinergically induced active sleep in the cat. J Neurosci 2000; 20:3319-3327.
13
14. Zemlan FP, Behbehani MM. Nucleus cuneiformis and pain modulation: anatomy and behavioral pharmacology. Brain Res 1988; 453:89-102.
14
15. Korte SM, Jaarsma D, Luiten PGM, Bohus B. Mesencephalic cuneiform nucleus and its ascending and descending projections serve stress-related cardiovascular responses in the rat. J Auton Nerv Syst 1992; 41:157-176.
15
16. Lam W, Verberne AJ. Cuneiform nucleus stimulation-induced sympathoexcitation: role of adrenoceptors, excitatory amino acid and serotonin receptors in rat spinal cord. Brain Res 1997; 757:191-201.
16
17. Shafei MN, Nasimi A. Effect of glutamate stimulation of the cuneiform nucleus on cardiovascular regulation in anesthetized rats: Role of the pontine Kolliker-Fuse nucleus. Brain Res 2011; 1385:135-143.
17
18. Shafei MN, Niazmand S, Hosseini M, Daloee MH. Pharmacological study of cholinergic system on cardiovascular regulation in the cuneiform nucleus of rat. Neurosci Lett 2013; 549:12-7.
18
19. Farrokhi E, Shafei MN, Khajavirad A, Hosseini M, Bideskan ARE. Role of the nitrergic system of the cuneiform nucleus in cardiovascular responses in Urethane-Anesthetized male rats. Iran J Med Sci 2017; 42:473-478.
19
20. Ahlgren J, Porter K, Hayward LF. Hemodynamic responses and c-Fos changes associated with hypotensive hemorrhage: standardizing a protocol for severe hemorrhage in conscious rats. Am J Physiol Regul Integ Comparat Physiol 2007; 292:1862-1871.
20
21. Buller KM, Smith DW, Day TA. NTS catecholamine cell recruitment by hemorrhage and hypoxia. Neurorep 1999; 10:3853-3856.
21
22. Thrivikraman KV, Bereiter DA, Gann DS. Catecholamine activity in paraventricular hypothalamus after hemorrhage in cats. Am J Physiol Regul Integ Comparat Physiol 1989; 257:370-376.
22
23. Lam W, Gundlach AL, Verberne AJ. Neuronal activation in the forebrain following electrical stimulation of the cuneiform nucleus in the rat: hypothalamic expression of c-fos and NGFI-A messenger RNA. Neurosci 1997; 78:1069-1085.
23
24. Luna-Munguia H, Manuel-Apolinar L, Rocha L, Meneses A. 5-HT 1A receptor expression during memory formation. Psychopharmacol 2005; 181:309-318.
24
25. Shafei MN, Nikyar T, Hosseini M, Niazmand S, Paseban M. Cardiovascular effects of nitrergic system of the pedunculopontine tegmental nucleus in anesthetized rats. Iran J Basic Med Sci 2017; 20:776-781.
25
26. Paxinos G, Watson C. The rat brain in stereotaxix coordinates. Qingchuan Zhuge translate 2005;32: 98-106.
26
27. Pasandi H, Abbaspoor S, Shafei MN, Hosseini M, Khajavirad A. GABAA receptor in the Pedunculopontine tegmental (PPT) nucleus: Effects on cardiovascular system. Pharmacol Rep 2018; 70:1001-1009.
27
28. Helke C, McDonald C, Phillips E. Hypotensive effects of 5-HT1A receptor activation: ventral medullary sites and mechanisms of action in the rat. J Auton Nerv Syst 1993; 42:177-188.
28
29. Miyawaki T, Goodchild AK, Pilowsky PM. Rostral ventral medulla 5-HT1A receptors selectively inhibit the somatosympathetic reflex. Am J Physiol Regul Integ Comparat Physiol 2001; 280:1261-1268.
29
30. Verberne AJ. Cuneiform nucleus stimulation produces activation of medullary sympathoexcitatory neurons in rats. Am J Physiol 1995; 268:752-758.
30
31. Behbehani MM, Zemlan FP. Response of nucleus raphe magnus neurons to electrical stimulation of nucleus cuneiformis: role of acetylcholine. Brain Res 1986; 369:110-118.
31
32. Richter R, Behbehani M. Evidence for glutamic acid as a possible neurotransmitter between the mesencephalic nucleus cuneiformis and the medullary nucleus raphe magnus in the lightly anesthetized rat. Brain Res 1991; 544:279-286.
32
33. Portas CM, Thakkar M, Rainnie D, McCarley RW. Microdialysis perfusion of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the dorsal raphe nucleus decreases serotonin release and increases rapid eye movement sleep in the freely moving cat. J Neurosci 1996; 16:2820-2828.
33
ORIGINAL_ARTICLE
Trastuzumab increases pulmonary vein arrhythmogenesis through modulating pulmonary vein electrical and conduction properties via phosphatidylinositol 3-kinase signaling
Objective(s): Drug-induced atrial fibrillation (AF) is considered an adverse effect of chemotherapeutic drugs. AF is a crucial risk factor for stroke, heart failure, myocardial infarction, and mortality. Pulmonary veins (PVs) are considered triggers inducing AF, and the sinoatrial node (SAN) may modulate PV activity and participate in AF genesis. AF was associated with early discontinuation of trastuzumab in patients with breast cancer. However, whether trastuzumab directly modulates the electrophysiological characteristics of PV and SAN remains unclear. Materials and Methods: ECG and conventional microelectrode system were used to record rabbit heart rhythm in vivo and electrical activities in vitro from isolated SAN, PV, and SAN-PV preparations. Results: Trastuzumab reduced the beating rate in isolated PV and SAN preparations at 1, 10, and 30 μM (particularly in isolated SAN preparations) and induced burst firings in isolated PV preparations at 10 μΜ. In addition, trastuzumab (10 μM) induced SAN-PV conduction block and burst firings, which were blocked by wortmannin (a PI3K inhibitor, 100 nM). Similarly, ECG recordings showed that acute intravenous administration of trastuzumab (10 mg/kg) reduced rabbit heart rates. Conclusion: Trastuzumab increased PV arrhythmogenesis through interfering with PI3K signaling, which may contribute to the genesis of AF.
https://ijbms.mums.ac.ir/article_15568_a1bd6a01e5c0ab9221636a483ff6da3c.pdf
2020-07-01
865
870
10.22038/ijbms.2020.44651.10432
Atrial fibrillation
Electrophysiology
PI3 Kinase
Pulmonary vein
Trastuzumab
Jun-Hei
Chang
junheic@gmail.com
1
Department of Medical, Tri-Service General Hospital Songshan Branch, National Defense Medical Center, Taipei, Taiwan
AUTHOR
Chen-Chuan
Cheng
cccheng7@yahoo.com.tw
2
Department of Cardiology, Chi-Mei Medical Center, Tainan, Taiwan
AUTHOR
Yen-Yu
Lu
yolu59@yahoo.com.tw
3
Division of Cardiology, Department of Internal Medicine, Sijhih Cathay General Hospital, New Taipei City, Taiwan
AUTHOR
Yao-Chang
Chen
bme02@ndmctsgh.edu.tw
4
Department of Biomedical Engineering, National Defense Medical Center, Taipei, Taiwan
AUTHOR
Shih-Ann
Chen
epsachen@ms41.hinet.net
5
Heart Rhythm Center and Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
AUTHOR
Yi-Jen
Chen
yjchen@tmu.edu.tw
6
Cardiovascular Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
LEAD_AUTHOR
1. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation 2011;124:2264-2274.
1
2. Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GYH. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest 2015;147:109-119.
2
3. Khan MA, Ahmed F, Neyses L, Mamas MA. Atrial fibrillation in heart failure: The sword of Damocles revisited. World J Cardiol 2013;5:215-227.
3
4. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009;30:1038-1045.
4
5. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study Stroke 1997;28:316-321.
5
6. Cheng WL, Kao YH, Chen SA, Chen YJ. Pathophysiology of cancer therapy-provoked atrial fibrillation. Int J Cardiol 2016;219:186-194.
6
7. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 2014;63:945-953.
7
8. Melloni C, Shrader P, Carver J, Piccini JP, Thomas L, Fonarow GC, et al. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. E Eur Heart J Qual Care Clin Outcomes 2017;3:192-197.
8
9. Ording AG, Horvath-Puho E, Adelborg K, Pedersen L, Prandoni P, Sorensen HT. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med 2017;6:1165-1172.
9
10. Adão R, de Keulenaer G, Leite-Moreira A, Brás-Silva C. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies. Rev Port Cardiol 2013;32:395-409.
10
11. Tamargo J, Caballero R, Delpon E. Drug-induced atrial fibrillation: does it matter? Discov Med 2012;14:295-299.
11
12. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25.
12
13. Soo Park J, Youn JC, Shim CY, Hong GR, Lee CK, Kim JH, et al. Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Oncotarget 2017;8:61837-61845.
13
14. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009;33:315-318.
14
15. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
15
16. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
16
17. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
17
18. Bregni G, Galli G, Gevorgyan A, de Braud F, Di Cosimo S. Trastuzumab cardiac toxicity: a problem we put our heart into. Tumori 2016;102:1-5.
18
19. Denegri A, Moccetti T, Moccetti M, Spallarossa P, Brunelli C, Ameri P. Cardiac toxicity of trastuzumab in elderly patients with breast cancer. J Geriatr Cardiol 2016;13:355-363.
19
20. Hamirani Y, Fanous I, Kramer CM, Wong A, Salerno M, Dillon P. Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study. Med Oncol 2016;33:82-89.
20
21. Jain D, Russell RR, Schwartz RG, Panjrath GS, Aronow W. Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions. Curr Cardiol Rep 2017;19:36-47.
21
22. Leung HW, Chan AL. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data. Expert Opin Drug Saf 2015;14:1661-1671.
22
23. Mantarro S, Rossi M, Bonifazi M, D’Amico R, Blandizzi C, La Vecchia C, et al. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med 2016;11:123-140.
23
24. Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, et al. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. J Cardiovasc Med (Hagerstown) 2016;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e19-e26.
24
25. Tang GH, Acuna SA, Sevick L, Yan AT, Brezden-Masley C. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single “real-world” setting. Med Oncol 2017;34:154.
25
26. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 2014;3:e000472.
26
27. Wang SY, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP, et al. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Res Treat 2014;146:411-419.
27
28. Martinello R, Becco P, Vici P, Airoldi M, Del Mastro L, Garrone O, et al. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. Breast J 2019;25:444-449.
28
29. Yuan M, Tse G, Zhang Z, Han X, Wu WKK, Li G, et al. The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta-analysis. Cardiovasc Ther 2018;36:e12475.
29
30. Fu YF, Gui R, Liu J. HER-2-induced PI3K signaling pathway was involved in the pathogenesis of gastric cancer. Cancer Gene Ther 2015;22:145-153.
30
31. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, et al. Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. PLoS One 2012;7:e39626.
31
32. Pretorius L, Du XJ, Woodcock EA, Kiriazis H, Lin RC, Marasco S, et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol 2009;175:998-1009.
32
33. Fink RI, Kolterman OG, Griffin J, Olefsky JM. Mechanisms of insulin resistance in aging. J Clin Invest. 1983;71:1523–1535.
33
34. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes. 2005;54:2360–2364.
34
35. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473–481.
35
36. Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, et al. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J 2009;23:3171-3178.
36
37. Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumab-induced cardiac dysfunction: A ‘dual-hit’. Exp Clin Cardiol 2011;16:70-74.
37
38. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-226.
38
39. Chen SA, Hsieh MH, Tai CT, Tsai CF, Prakash VS, Yu WC, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999;100:1879-1886.
39
40. Pappone C, Oreto G, Rosanio S, Vicedomini G, Tocchi M, Gugliotta F, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001;104:2539-2544.
40
41. Chen YC, Lu YY, Cheng CC, Lin YK, Chen SA, Chen YJ. Sinoatrial node electrical activity modulates pulmonary vein arrhythmogenesis. Int J Cardiol 2014;173:447-452.
41
42. Tsai CF, Chen YC, Lin YK, Chen SA, Chen YJ. Electromechanical effects of the direct renin inhibitor (aliskiren) on the pulmonary vein and atrium. Basic Res Cardiol 2011;106:979-993.
42
43. Chang CJ, Chen YC, Kao YH, Lin YK, Chen SA, Chen YJ. Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium. Circ Arrhythm Electrophysiol 2012;5:1176-1183.
43
44. Lo LW, Chen YC, Chen YJ, Wongcharoen W, Lin CI, Chen SA. Calmodulin kinase II inhibition prevents arrhythmic activity induced by alpha and beta adrenergic agonists in rabbit pulmonary veins. Eur J Pharmacol 2007;571:197-208.
44
45. Quartino AL, Hillenbach C, Li J, Li H, Wada RD, Visich J, et al. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer. Cancer Chemother Pharmacol 2016;77:77-88.
45
46. Olin RL, Desai SS, Fox K, Davidson R. Non-myopathic cardiac events in two patients treated with trastuzumab. Breast J 2007;13:211-212.
46
47. McMullen JR, Amirahmadi F, Woodcock EA, Schinke-Braun M, Bouwman RD, Hewitt KA, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A 2007;104:612-617.
47
48. McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014;124:3829-3830.
48
49. Yang KC, Tseng YT, Nerbonne JM. Exercise training and PI3Kalpha-induced electrical remodeling is independent of cellular hypertrophy and Akt signaling. J Mol Cell Cardiol 2012;53:532-541.
49
50. Schluter KD, Goldberg Y, Taimor G, Schafer M, Piper HM. Role of phosphatidylinositol 3-kinase activation in the hypertrophic growth of adult ventricular cardiomyocytes. Cardiovasc Res 1998;40:174-181.
50
51. Yano N, Tseng A, Zhao TC, Robbins J, Padbury JF, Tseng YT. Temporally controlled overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility--a new transgenic model. Am J Physiol Heart Circ Physiol 2008;295:H1690-1694.
51
52. Lu Z, Jiang YP, Wang W, Xu XH, Mathias RT, Entcheva E, et al. Loss of cardiac phosphoinositide 3-kinase p110 alpha results in contractile dysfunction. Circulation 2009;120:318-325.
52
53. Blazek M, Santisteban TS, Zengerle R, Meier M. Analysis of fast protein phosphorylation kinetics in single cells on a microfluidic chip. Lab Chip 2015;15:726-734.
53
54. Prabakaran SL, Lippens G, Steen H, Gunawardena J. Post-translational modification: nature’s escape from genetic imprisonment and the basis for dynamic information encoding. Wiley Interdiscip Rev Syst Biol Med 2012;4:565-583.
54
55. Zhu S, Cawley SM, Bloch KD, Huang PL. Trastuzumab and lapatinib differ in effects on calcium cycling and HER2 expression in human embryonic stem cell-derived cardiomyocytes. Cardio Vasc Syst 2013; 1:10.
55
ORIGINAL_ARTICLE
Effects of 8-hydroxyquinoline-coated graphene oxide on cell death and apoptosis in MCF-7 and MCF-10 breast cell lines
Objective(s): Breast cancer is a devastating disease related to women. The anticancer properties of 8-hydroxyquinoline (8HQ) and the increasing use of graphene oxide (GO), as a drug delivery system with anti-cancerous properties, led us to investigate the toxicity and apoptosis-induction capability of 8HQ-coated GO on breast cancer cells compared with normal breast cells.Materials and Methods: Breast cancer (MCF-7) and normal breast (MCF-10) cell lines were treated with several doses of 8-HQ-coated GO for 12, 24, and 48 hr. The toxicity of the nanocomposite was measured using MTT assay and the effect of the nanocomposite on cell apoptosis was determined by examining the expression of P53, P21, Bax, and BCL2 genes, as well as Annexin-V /PI apoptosis assay.Results: There were significantly increased cell deaths in nanocomposite-treated MCF-7 breast cancer cells, compared with treated normal breast cells. Significantly increased expression of P53, P21, and Bax genes and reduced expression of BCL2 gene were found in the treated breast cancer cell line compared with the normal cell line. Annexin-V/PI assay also illustrated significant induction of apoptosis in MCF-7 following nanocomposite treatment.Conclusion: Overall, 8HQ-coated GO has toxicity for breast cancer cell lines and one of the mechanisms through which this nanocomposite can induce cell death is the induction of apoptosis. With complementary in vitro and in vivo studies, this nanocomposite can be suggested as a nano-drug with anti-cancer properties.
https://ijbms.mums.ac.ir/article_15572_7c78154dc24fbdc3d41dae4f063a832e.pdf
2020-07-01
871
878
10.22038/ijbms.2020.41277.9751
8-Hydroxyquinoline
Apoptosis
Breast Cancer
Cytotoxicity
Graphene oxide
Firoozeh
Kheiltash
kheiltash83@yahoo.com
1
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Kazem
Parivar
kazem_parivar@yahoo.com
2
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
LEAD_AUTHOR
Nasim
Hayati Roodbari
nasimhayati@yahoo.com
3
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Behnam
Sadeghi
behnamsg@yahoo.com
4
Cancer Immunotherapy and Regenerative Medicine, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
AUTHOR
Alireza
Badiei
abadiei@khayam.ut.ac.ir
5
School of Chemistry, College of Science, University of Tehran, Tehran, Iran
AUTHOR
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA cancer J Clin 2018; 68:394-424.
1
2. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma K. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res 2010; 1:109-126.
2
3. Stewart BW. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 1994; 86:1286-1296.
3
4. Dakubo GD. Mitochondrial genetics and cancer: Springer Science & Business Media; 2010.
4
5.El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825.
5
6. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown J, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-1501.
6
7. Fulda S, Debatin K-M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25:4798.
7
8. Pierson HO. Handbook of carbon, graphite, diamonds and fullerenes: processing, properties and applications: William Andrew; 2012.
8
9. Du W, Jiang X, Zhu L. From graphite to graphene: direct liquid-phase exfoliation of graphite to produce single-and few-layered pristine graphene. J Mater Chem A Mater 2013; 1:10592-10606.
9
10. Paulchamy B, Arthi G, Lignesh B. A simple approach to stepwise synthesis of graphene oxide nanomaterial. J Nanomed Nanotechnol 2015; 6:253-256.
10
11. Wei J, Vo T, Inam F. Epoxy/graphene nanocomposites–processing and properties: A review. RSC Adv 2015; 5:73510-73524.
11
12. Srivastava V, Negi AS, Kumar J, Gupta M, Khanuja SP. Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg Med Chem 2005; 13:5892-5908.
12
13. Afzal O, Kumar S, Haider MR, Ali MR, Kumar R, Jaggi M, et al. A review on anticancer potential of bioactive heterocycle quinoline. Eur J Med Chem 2015; 97:871-910.
13
14. Xu H, Chen W, Zhan P, Liu X. 8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential. Med Chem Comm 2015; 6:61-74.
14
15. Bianco A. Graphene: safe or toxic? The two faces of the medal. Angew Chem Int Ed Engl 2013; 52:4986-4997.
15
16. Hummers Jr WS, Offeman RE. Preparation of graphitic oxide. J Am Chem Soc 1958; 80:1339-1339.
16
17. Badiei A, Goldooz H, Ziarani GM. A novel method for preparation of 8-hydroxyquinoline functionalized mesoporous silica: Aluminum complexes and photoluminescence studies. Appl Surf Sci 2011; 257:4912-4918.
17
18. Goldooz H, Badiei A, Shiravand G, Ghasemi JB, Ziarani GM. A highly selective Ag+ sensor based on 8-hydroxyquinoline functionalized graphene oxide-silica nanosheet and its logic gate behaviour. J Mater Sci 2019; 30:17693-17705.
18
19. Priyadarsini RV, Murugan RS, Maitreyi S, Ramalingam K, Karunagaran D, Nagini S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-κB inhibition. Eur J Pharmacol 2010; 649:84-91.
19
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. methods 2001; 25:402-408.
20
21. Lei H, Xie M, Zhao Y, Zhang F, Xu Y, Xie J. Chitosan/sodium alginate modificated graphene oxide-based nanocomposite as a carrier for drug delivery. Ceram Int 2016; 42:17798-17805.
21
22. Liu Z, Robinson JT, Sun X, Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J AM Chem Soc 2008; 130:10876-10877.
22
23. Yadav N, Kumar N, Prasad P, Shirbhate S, Sehrawat S, Lochab B. Stable dispersions of covalently tethered polymer improved graphene oxide nanoconjugates as an effective vector for siRNA delivery. ACS Appl Mater Interfaces 2018; 10:14577-14593.
23
24. Chang Y, Yang S-T, Liu J-H, Dong E, Wang Y, Cao A, et al. In vitro toxicity evaluation of graphene oxide on A549 cells. Toxicol Lett 2011; 200:201-210.
24
25. Chen L, Hu P, Zhang L, Huang S, Luo L, Huang C. Toxicity of graphene oxide and multi-walled carbon nanotubes against human cells and zebrafish. Sci China Chem 2012; 55:2209-2216.
25
26. Alibolandi M, Mohammadi M, Taghdisi SM, Ramezani M, Abnous K. Fabrication of aptamer decorated dextran coated nano-graphene oxide for targeted drug delivery. Carbohydr Polym 2017; 155:218-229.
26
27. Liu Y, Zhong H, Qin Y, Zhang Y, Liu X, Zhang T. Non-covalent hydrophilization of reduced graphene oxide used as a paclitaxel vehicle. RSC Adv 2016; 6:30184-30193.
27
28. Chaudhari NS, Pandey AP, Patil PO, Tekade AR, Bari SB, Deshmukh PK. Graphene oxide based magnetic nanocomposites for efficient treatment of breast cancer. Mater Sci Eng C 2014; 37:278-285.
28
29. Hu W, Peng C, Luo W, Lv M, Li X, Li D, et al. Graphene-based antibacterial paper. ACS Nano 2010; 4:4317-4323.
29
30. Krajnović T, Maksimović-Ivanić D, Mijatović S, Drača D, Wolf K, Edeler D, et al. Drug delivery system for emodin based on mesoporous silica SBA-15. Nanomaterials 2018; 8:322-337.
30
31. Wang D, Huang J, Wang X, Yu Y, Zhang H, Chen Y, et al. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. Biomaterials 2013; 34:7662-7673.
31
32. Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev 2012; 41:2740-2779.
32
33. Liu W, Li X, Wong Y-S, Zheng W, Zhang Y, Cao W, et al. Selenium nanoparticles as a carrier of 5-fluorouracil to achieve anticancer synergism. Acs Nano 2012; 6:6578-6591.
33
34. Lv Y, Tao L, Bligh SA, Yang H, Pan Q, Zhu L. Targeted delivery and controlled release of doxorubicin into cancer cells using a multifunctional graphene oxide. Mater Sci Eng C 2016; 59:652-660.
34
35. Jafarizad A, Aghanejad A, Sevim M, Metin Ö, Barar J, Omidi Y, et al. Gold nanoparticles and reduced graphene oxide‐gold nanoparticle composite materials as covalent drug delivery systems for breast cancer treatment. ChemistrySelect 2017; 2:6663-6672.
35
36. Fan L, Ge H, Zou S, Xiao Y, Wen H, Li Y, et al. Sodium alginate conjugated graphene oxide as a new carrier for drug delivery system. Int J Biol Macromol 2016; 93:582-590.
36
37. Fiorillo M, Verre AF, Iliut M, Peiris-Pagés M, Ozsvari B, Gandara R, et al. Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”. Oncotarget 2015; 6:3553-3562.
37
38. Yoon HH, Bhang SH, Kim T, Yu T, Hyeon T, Kim BS. Dual roles of graphene oxide in chondrogenic differentiation of adult stem cells: Cell‐adhesion substrate and growth factor‐delivery carrier. Adv Func Mater 2014; 24:6455-6464.
38
39. Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des Devel Ther 2013; 7:1157.
39
40. Zhai S, Yang L, Cui QC, Sun Y, Dou QP, Yan B. Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. J Biol Inorg Chemi 2010; 15:259-269.
40
41. Wang N, Świtalska M, Wu MY, Imai K, Ngoc TA, Pang CQ, et al. Synthesis and in vitro cytotoxic effect of 6-amino-substituted 11H-and 11Me-indolo [3, 2-c] quinolines. Eur J Med Chem 2014; 78:314-323.
41
42. Xiao Z, Lei F, Chen X, Wang X, Cao L, Ye K, et al. Design, synthesis, and antitumor evaluation of quinoline‐imidazole derivatives. Arch Pharm 2018; 351:1700407.
42
43. Chen C, Hou X, Wang G, Pan W, Yang X, Zhang Y, et al. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors. Eur J Med Chem 2017; 133:11-23.
43
44. Qin Q-P, Chen Z-F, Qin J-L, He X-J, Li Y-L, Liu Y-C, et al. Studies on antitumor mechanism of two planar platinum (II) complexes with 8-hydroxyquinoline: synthesis, characterization, cytotoxicity, cell cycle and apoptosis. Eur J Med Chem 2015; 92:302-313.
44
45. Chan SH, Chui CH, Chan SW, Kok SHL, Chan D, Tsoi MYT, et al. Synthesis of 8-hydroxyquinoline derivatives as novel antitumor agents. ACS Med Chemlett 2012; 4:170-174.
45
ORIGINAL_ARTICLE
Comparison of the effects of intramyocardial and intravenous injections of human mesenchymal stem cells on cardiac regeneration after heart failure
Objective(s): Existing studies have demonstrated that intravenous and intramyocardial-administrated mesenchymal stem cells (MSCs) lead to tissue repair after cardiac disorders. We compared the efficiency of both administration methods.Materials and Methods: A rat model of isoproterenol-induced heart failure (ISO-HF) was established to compare the effects of intravenous and intramyocardial-administrated MSCs on cardiac fibrosis and function. The animals were randomly assigned into six groups: i) control or normal, ii) ISO-HF (HF) iii) ISO-HF rats treated with intramyocardial administration of culture medium (HF+IM/CM), iv) ISO-HF rats treated with intravenous administration of culture medium ( HF+IV/CM), v) ISO-HF rats treated with intravenous administration of MSCs (HF+IV/MSCs), vi) ISO-HF rats treated with intramyocardial administration of MSCs ( HF+IM/MSCs). Cultured MSCs and culture medium were administrated at 4 weeks after final injection of ISO. Heart function, identification of MSCs, osteogenic differentiation, adipogenic differentiation, cardiac fibrosis and tissue damage were evaluated by echocardiography, flow-cytometery, von Kossa, oil red O, Masson’s trichrome and H & E staining, respectively. Results: Both intravenous and intramyocardial MSCs therapy significantly improved heart function and reduced cardiac fibrosis and tissue damage (P<0.05), whereas the cultured medium had no beneficial effects. Conclusion: In sum, our results confirm the validity of both administration methods in recovery of HF, but more future research is required.
https://ijbms.mums.ac.ir/article_15493_b42d5768a50a98ad2d8677f4eb310576.pdf
2020-07-01
879
885
10.22038/ijbms.2020.40886.9660
Heart function
Intramyocardial injection
Intravenous injection
Isoproterenol-induced heart failure
Mesenchymal stem cells
Behnaz
Mokhtari
behnaz.sa.mokhtari@gmail.com
1
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Nahid
Aboutaleb
dr_nabo40@yahoo.com
2
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Donya
Nazarinia
e_nazarinia@yahoo.com
3
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Mahin
Nikougoftar
nikougoftar@gmail.com
4
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
AUTHOR
Seyed Mohammad Taghi
Razavi Tousi
razavitosee@yahoo.com
5
Medical Biotechnology Research Center, Guilan University of Medical Sciences, Rasht, Iran
AUTHOR
Mohammad
Molazem
mmolazem@ut.ac.ir
6
Department of Veterinary Diagnostic Imaging, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
AUTHOR
Mohammad-Reza
Azadi
7
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
1. Pfau D, Thorn SL, Zhang J, Mikush N, Renaud JM, Klein R, et al. Angiotensin receptor neprilysin inhibitor attenuates myocardial remodeling and improves infarct perfusion in experimental heart failure. Sci Rep 2019; 9:5791.
1
2. Amani H, Habibey R, Hajmiresmail S, Latifi S, Pazoki-Toroudi H, Akhavan O. Antioxidant nanomaterials in advanced diagnoses and treatments of ischemia reperfusion injuries. J Mater Chem B 2017; 5:9452-9476.
2
3. Saporito F, Baugh LM, Rossi S, Bonferoni MC, Perotti C, Sandri G, et al. In Situ gelling scaffolds loaded with platelet growth factors to improve cardiomyocyte survival after ischemia. ACS Biomater Sci Eng 2018; 5:329-338.
3
4. Li L, Zhang S, Zhang Y, Yu B, Xu Y, Guan Z. Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure. Mol Biol Rep 2009; 36:725-731.
4
5. Zhang W, Zhang J, Kang Y, Liu J, Wang X, Xu Q, et al. Cardioprotective effects of oxymatrine on isoproterenol-induced heart failure via regulation of DDAH/ADMA metabolism pathway in rats. Eur J Pharmacol 2014; 745:29-35.
5
6. Chia N, Fulcher J, Keech A. Beta‐blocker, angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker, nitrate‐hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID2): an evidence‐based mnemonic for the treatment of systolic heart failure. Intern Med J 2016; 46:653-662.
6
7. Li L, Zhang Y, Li Y, Yu B, Xu Y, Zhao S, et al. Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol‐induced global heart failure. Transpl Int, 2008; 21:1181-1189.
7
8. Amani H, Mostafavi E, Arzaghi H, Davaran S, Akbarzadeh A, Akhavan O, et al. Three-dimensional graphene foams: synthesis, properties, biocompatibility, biodegradability, and applications in tissue engineering. ACS Biomater Sci Eng 2018; 5:193-214.
8
9. Sun S-q, Wang X-t, Qu X-f, Li Y, Yu Y, Song Y, et al. Increased expression of myocardial semaphorin 3A in isoproterenol-induced heart failure rats. Chin Med J 2011; 124:2173.
9
10. Arabian M, Aboutaleb N, Soleimani M, Mehrjerdi FZ, Ajami M, Pazoki-Toroudi H. Role of morphine preconditioning and nitric oxide following brain ischemia reperfusion injury in mice. Iran J Basic Med Sci 2015; 18:14-21.
10
11. Pazoki-Toroudi H, Nassiri-Kashani M, Tabatabaie H, Ajami M, Habibey R, Shizarpour M, et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. J Dermatol Treat 2010; 21:212-216.
11
12. Kumar M, Kasala ER, Bodduluru LN, Dahiya V, Lahkar M. Baicalein protects isoproterenol induced myocardial ischemic injury in male Wistar rats by mitigating oxidative stress and inflammation. Inflamm Res 2016; 65:613-622.
12
13. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells-current trends and future prospective. Biosci Rep 2015; 35:e00191.
13
14. Amani H, Arzaghi H, Bayandori M, Dezfuli AS, Pazoki‐Toroudi H, Shafiee A, et al. Controlling cell behavior through the design of biomaterial surfaces: A focus on surface modification techniques. Adv Mater Interfaces 2019:1900572.
14
15. Premer C, Blum A, Bellio MA, Schulman IH, Hurwitz BE, Parker M, et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine 2015; 2:467-475.
15
16. Tousi SMTR, Faghihi M, Nobakht M, Molazem M, Kalantari E, Azar AD, et al. Improvement of heart failure by human amniotic mesenchymal stromal cell transplantation in rats. J Tehran Heart Cent 2016; 11:123-138.
16
17. Malliaras K, Li T-S, Luthringer D, Terrovitis J, Cheng K, Chakravarty T, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 2011; 125:100-112.
17
18. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008; 103:1204-1219.
18
19. Li Y, Zhang Y, Li Z, Zhou K, Feng N. Exosomes as Carriers for Antitumor Therapy. ACS Biomater Sci Eng 2019; 5, 10, 4870-4881.
19
20. Nazarinia D, Aboutaleb N, Gholamzadeh R, Maleki SN, Mokhtari B, Nikougoftar M. Conditioned medium obtained from human amniotic mesenchymal stem cells attenuates focal cerebral ischemia/reperfusion injury in rats by targeting mTOR pathway. J Chem Neuroanat 2019; 102:101707.
20
21. Amirfarhangi A, Dezfouli M, Abarkar M, Rakhshan K, Aboutaleb N. Protective Role of Bone Marrow Derived Mesenchymal Stem Cells-Conditioned Medium in the Infarcted Myocardium: The Potential Role of Selected Cytokines. Int J Stem Cell Res Transplant 2016; 4:243-250.
21
22. Lee S-T, White AJ, Matsushita S, Malliaras K, Steenbergen C, Zhang Y, et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol 2011; 57:455-465.
22
23. Amado LC, Saliaris AP, Schuleri KH, John MS, Xie J-S, Cattaneo S, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci 2005; 102:11474-11479.
23
24. Luger D, Lipinski MJ, Westman PC, Glover DK, Frias JC, Albelda M, et al. Intravenously-delivered mesenchymal stem cells: systemic anti-inflammatory effects improve left ventricular dysfunction in acute myocardial infarction and ischemic cardiomyopathy. Circ Res 2017; 102: 11474-11479.
24
25. Faezi M, Maleki SN, Aboutaleb N, Nikougoftar M. The membrane mesenchymal stem cell derived conditioned medium exerts neuroprotection against focal cerebral ischemia by targeting apoptosis J Chem Neuroanat 2018; 94:21-31.
25
26. Aboutaleb N, Faezi M, Maleki SN, Nazarinia D, Tousi SMTR, Hashemirad N. Conditioned medium obtained from mesenchymal stem cells attenuates focal cerebral ischemia reperfusion injury through activation of ERK1/ERK2-BDNF signaling pathway. J Chem Neuroanat 2019; 97:87-98.
26
27. Nasseri Maleki S, Aboutaleb N, Nazarinia D, Allahverdi Beik S, Qolamian A, Nobakht M. Conditioned medium obtained from human amniotic membrane-derived mesenchymal stem cell attenuates heart failure injury in rats. Iran J Basic Med Sci 2019; 22:1253-1258.
27
28. Meeran MFN, Jagadeesh GS, Selvaraj P. Catecholamine toxicity triggers myocardial membrane destabilization in rats: thymol and its counter action. RSC Adv. 2015; 5:43338-43344.
28
29. Tousi SMTR, Amirizadeh N, Nasirinezhad F, Nikougoftar M, Ganjibakhsh M, Aboutaleb N. A rapid and cost-effective protocol for isolating mesenchymal stem cells from the human amniotic membrane. Galen Med J 2017; 6:217-225.
29
30. Li X, Yu X, Lin Q, Deng C, Shan Z, Yang M, et al. Bone marrow mesenchymal stem cells differentiate into functional cardiac phenotypes by cardiac microenvironment. J Mol Cell Cardiol 2007; 42:295-303.
30
31. Li W, Gan R, Sun G. Chronic treatment of enbrel in rats with isoproterenol-induced congestive heart failure limits left ventricular dysfunction and remodeling. Chin Med J 2002; 115:1166-1169.
31
32. Rodriguez AJ, Mousa A, Ebeling PR, Scott D, De Courten B. Effects of vitamin D supplementation on inflammatory markers in heart failure: A systematic review and meta-analysis of randomized controlled trials. Sci Rep 2018; 8:1169.
32
33. Amani H, Mostafavi E, Alebouyeh MR, Arzaghi H, Akbarzadeh A, Pazoki-Toroudi H, et al. Would Colloidal Gold Nanocarriers Present An Effective Diagnosis Or Treatment For Ischemic Stroke? Int J Nanomed 2019; 14:8013.
33
34. Amani H, Habibey R, Shokri F, Hajmiresmail SJ, Akhavan O, Mashaghi A, et al. Selenium nanoparticles for targeted stroke therapy through modulation of inflammatory and metabolic signaling. Sci Rep 2019; 9:6044.
34
35. Amani H, Kazerooni H, Hassanpoor H, Akbarzadeh A, Pazoki-Toroudi H. Tailoring synthetic polymeric biomaterials towards nerve tissue engineering: a review. Artif Cells Nanomed Biotechnol 2019; 47:3524-3539.
35
36. Javedan G, Shidfar F, Davoodi SH, Ajami M, Gorjipour F, Sureda A, et al. Conjugated linoleic acid rat pretreatment reduces renal damage in ischemia/reperfusion injury: Unraveling antiapoptotic mechanisms and regulation of phosphorylated mammalian target of rapamycin. Mol Nutr Food Res 2016; 60:2665-2677.
36
37. Firooz A, Bouzari N, Mojtahed F, Pazoki-Toroudi H, Nassiri-Kashani M, Davoudi M, et al. Topical immunotherapy with diphencyprone in the treatment of extensive and/or long-lasting alopecia areata 11. J Eur Acad Dermatol Venereol 2005; 19:393-394.
37
38. Booth EA, Lucchesi BR. Estrogen-mediated protection in myocardial ischemia-reperfusion injury. Cardiovasc Toxicol 2008; 8:101-113.
38
39. Cheng G, Labedz-Maslowska A, Berdecka D, Xuan Y-T, Samanta A, Girgis M, et al. Intramyocardial Injection of MSC-derived Extracellular Vesicles Confers Superior Cardiac Repair After a Reperfused Myocardial Infarction. Circulation 2015; 132:A16673.
39
40. Jiang Q, Yu T, Huang K, Zhang H, Zheng Z, Hu S. Systemic redistribution of the intramyocardially injected mesenchymal stem cells by repeated remote ischaemic post‐conditioning. J Cell Mol Med 2018; 22:417-428.
40
41. Wang W, Jin P, Wang L, Yang Z, Hu S, Gao B, et al. Impact of escaped bone marrow mesenchymal stromal cells on extracardiac organs after intramyocardial implantation in a rat myocardial infarction model. Cell Transplant 2010; 19:1599-1607.
41
42. Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, et al. Enhanced effect of human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and restore cardiac function after myocardial infarction. Circulation 2012; 112.131110.
42
43. Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M, et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Phys Heart Circ Phys 2004; 287:H2670-H2676.
43
44. Lim M, Wang W, Liang L, Han Z-b, Li Z, Geng J, et al. Intravenous injection of allogeneic umbilical cord-derived multipotent mesenchymal stromal cells reduces the infarct area and ameliorates cardiac function in a porcine model of acute myocardial infarction. Stem Cell Res Ther 2018; 9:129.
44
ORIGINAL_ARTICLE
Anti-cancer properties of Escherichia coli Nissle 1917 against HT-29 colon cancer cells through regulation of Bax/Bcl-xL and AKT/PTEN signaling pathways
Objective(s): Chemotherapies used to treat colon cancer might often fail due to the emergence of chemoresistance and side effects. Escherichia coli Nissle 1917 (EcN) is a beneficial probiotic, whose molecular mechanisms in the prevention of colon cancer are yet to be fully understood. The present study assessed the anti-cancer effects of EcN treatments in human colorectal cancer, HT-29 cell line, with the analysis of related mechanisms. Materials and Methods: The co-culture conditioned-media (CM) of EcN with adenocarcinoma HT-29 cells and heat-inactivated bacteria (HIB) were applied for the treatment of the HT-29 cells. To study the inhibition potential of CM and HIB on cancer cells, various cellular/molecular analyses were implemented, including DAPI-staining and DNA ladder assays, flow cytometry and Real-time quantitative PCR (qPCR), as well as Western blotting analyses.Results: Our results indicated that EcN could elicit apoptotic impacts on the colon cancer HT-29 cells by up-regulating PTEN and Bax and down-regulating AKT1 and Bcl-xL genes. Conclusion: Based on our findings, EcN is proposed as a useful supplemental probiotic treatment against colon cancer.
https://ijbms.mums.ac.ir/article_15520_46c1eecdd2eb476f7b2ac707a5de09e2.pdf
2020-07-01
886
893
10.22038/ijbms.2020.43016.10115
Akt
Apoptosis
cell signaling
Colon cancer
Escherichia coli Nissle1917
Siamak
Alizadeh
smk_alizadeh@yahoo.com
1
Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
AUTHOR
Abolghasem
Esmaeili
aesmaeili@sci.ui.ac.ir
2
Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
LEAD_AUTHOR
Yadollah
Omidi
yomidi@tbzmed.ac.ir
3
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
1. Khiavi MA, Safary A, Aghanejad A, Barar J, Rasta SH, Golchin A, et al. Enzyme-conjugated gold nanoparticles for combined enzyme and photothermal therapy of colon cancer cells. Colloids Surf. A Physicochem Eng Asp 2019; 572:333-344.
1
2. Vahed SZ, Barzegari A, Saadat YR, Goreyshi A, Omidi Y. Leuconostoc mesenteroides-derived anticancer pharmaceuticals hinder inflammation and cell survival in colon cancer cells by modulating NF-κB/AKT/PTEN/MAPK pathways. Biomed Pharmacother 2017; 94:1094-1100.
2
3. Salmanzadeh R, Eskandani M, Mokhtarzadeh A, Vandghanooni S, Ilghami R, Maleki H, et al . Propyl gallate (PG) and tert-butylhydroquinone (TBHQ) may alter the potential anti-cancer behavior of probiotics. Food Biosci 2018; 24:37-45.
3
4. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:1012-1018.
4
5. Jafari B, Rezaie A, Alizadeh S. Isolation and identification of potentially probiotic bacteria from traditional dairy products of Ardabil region in Iran. Ann Biol Res 2011; 2:311-317.
5
6. Wei MQ, Mengesha A, Good D, Anne J. Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett 2008; 259:16-27.
6
7. Westendorf AM, Gunzer F, Deppenmeier S, Tapadar D, Hunger JK, Schmidt MA, et al. Intestinal immunity of Escherichia coli Nissle 1917: a safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol 2005; 43:373-384.
7
8. Sharifi S, Barar J, Hejazi MS, Samadi N. Doxorubicin changes bax /Bcl-xL ratio, Caspase-8 and 9 in breast cancer cells. Adv Pharm Bull 2015; 5:351-359.
8
9. Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta 2015; 1855:104-121.
9
10. Pandurangan AK. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev 2013; 14:2201-2205.
10
11. Martínez-Maqueda D, Miralles B, Recio I. HT29 cell line. The Impact of Food Bioactives on Health: Springer, Cham; 2015. p. 113-124.
11
12. Van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol 2011; 731:237-245.
12
13. Rahbar Saadat Y, Saeidi N, Zununi Vahed S, Barzegari A, Barar J. An update to DNA ladder assay for apoptosis detection. Bioimpacts 2015; 5:25-28.
13
14. Rana C, Piplani H, Vaish V, Nehru B, Sanyal SN. Downregulation of PI3-K/Akt/PTEN pathway and activation of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in colon cancer. Mol Cell Biochem 2015; 402:225-241.
14
15. Asoudeh-Fard A, Barzegari A, Dehnad A, Bastani S, Golchin A, Omidi Y. Lactobacillus plantarum induces apoptosis in oral cancer KB cells through upregulation of PTEN and downregulation of MAPK signalling pathways. Bioimpacts 2017; 7:193-198.
15
16. Dehghani J, Adibkia K, Movafeghi A, Barzegari A, Pourseif MM, Maleki Kakelar H, et al. Stable transformation of Spirulina (Arthrospira) platensis: a promising microalga for production of edible vaccines. Appl Microbiol Biotechnol 2018; 102:9267-9278.
16
17. Gronbach K, Eberle U, Muller M, Olschlager TA, Dobrindt U, Leithauser F, et al. Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. Infect Immun 2010; 78:3036-3046.
17
18. Lin HC, Hsu CH, Chen HL, Chung MY, Hsu JF, Lien RI, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 2008; 122:693-700.
18
19. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007; 2:119-129.
19
20. Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazale T, Raupach B, et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun 2005; 73:1452-1465.
20
21. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn’s disease. Aliment Pharmacol Ther 2003; 18:45-56.
21
22. Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 2007; 297:151-162.
22
23. Abraha AM, Ketema EB. Apoptotic pathways as a therapeutic target for colorectal cancer treatment. World J Gastrointest Oncol 2016; 8:583-591.
23
24. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004; 15:171-176.
24
25. Palozza P, Torelli C, Boninsegna A, Simone R, Catalano A, Mele MC, et al. Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus pluvialis in human colon cancer cells. Cancer Lett 2009; 283:108-117.
25
26. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-562.
26
27.Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138:2073-2087 e2073.
27
28. Wang H, Bastian SE, Lawrence A, Howarth GS. Factors derived from Escherichia coli Nissle 1917, grown in different growth media, enhance cell death in a model of 5-fluorouracil-induced caco-2 intestinal epithelial cell damage. Nutr. Cancer 2015; 67:316-326.
28
29. Otte J-M, Mahjurian-Namari R, Brand S, Werner I, Schmidt WE, Schmitz F. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr. Cancer 2008; 61:103-113.
29
30. Nurmi JT, Puolakkainen PA, Rautonen NE. Bifidobacterium Lactis sp. 420 up-regulates cyclooxygenase (Cox)-1 and down-regulates Cox-2 gene expression in a Caco-2 cell culture model. Nutr. Cancer 2005; 51:83-92.
30
31. Iyer C, Kosters A, Sethi G, Kunnumakkara AB, Aggarwal BB, Versalovic J. Probiotic Lactobacillus reuteri promotes TNF‐induced apoptosis in human myeloid leukemia‐derived cells by modulation of NF‐κB and MAPK signalling. Cell Microbiol 2008; 10:1442-1452.
31
32. Kim Y, Oh S, Yun H, Oh S, Kim S. Cell‐bound exopolysaccharide from probiotic bacteria induces autophagic cell death of tumour cells. Lett Appl Microbiol 2010; 51:123-130.
32
33. Zhu Y, Luo TM, Jobin C, Young HA. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett 2011; 309:119-127.
33
34. Souza EL, Elian SD, Paula LM, Garcia CC, Vieira AT, Teixeira MM, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, the inflammatory response and clinical signs in a faecal transplantation model. J Med Microbiol 2016; 65:201-210.
34
35. Secher T, Kassem S, Benamar M, Bernard I, Boury M, Barreau F, et al. Oral administration of the probiotic strain Escherichia coli Nissle 1917 reduces susceptibility to neuroinflammation and repairs experimental autoimmune encephalomyelitis-induced intestinal barrier dysfunction. Front Immunol 2017; 8:1096.
35
36. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014; 7:473-487.
36
37. Saini MK, Sanyal SN. PTEN regulates apoptotic cell death through PI3-K/Akt/GSK3beta signaling pathway in DMH induced early colon carcinogenesis in rat. Exp Mol Pathol 2012; 93:135-146.
37
38. Zhang Y, Zhang Y, Xia L, Zhang X, Ding X, Yan F, et al. Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Appl Environ Microbiol 2012; 78:7603-7610.
38
39. Guzy C, Paclik D, Schirbel A, Sonnenborn U, Wiedenmann B, Sturm A. The probiotic Escherichia coli strain Nissle 1917 induces gammadelta T cell apoptosis via caspase- and FasL-dependent pathways. Int Immunol 2008; 20:829-840.
39
40. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3:453-458.
40
41. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA. Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol 2008; 10:1235-1248.
41
ORIGINAL_ARTICLE
Electroacupuncture reduces chronic fibromyalgia pain through attenuation of transient receptor potential vanilloid 1 signaling pathway in mouse brains
Objective(s): Fibromyalgia pain is a mysterious clinical pain syndrome, characterized by inflammation in the brain, whose molecular mechanisms are still unknown. Females are more commonly affected by fibromyalgia, exhibiting symptoms such as widespread mechanical pain, immune dysfunction, sleep disturbances, and poor quality of life. Electroacupuncture (EA) has been used to relieve several types of pain, including fibromyalgia pain.Materials and Methods: In the present study, we used dual injections of acidic saline into the gastrocnemius muscle to initiate a neural activation that resulted in fibromyalgia pain in mice. We used the Von Frey test to measure mechanical hyperalgesia and Western blot to measure protein levels. Results: Results indicated that mechanical hyperalgesia can be induced in mice for 4 weeks, suggesting the induction of chronic fibromyalgia (CFM). Furthermore, continuous EA treatment reliably attenuated the mechanical hyperalgesia, but not in the sham control group. Results also suggested that the mechanical hyperalgesia can be prevented in mice with TRPV1 gene deletion. Mice with CFM showed increased expressions of TRPV1, Nav1.7, and Nav1.8 in the dorsal root ganglion (DRG) and the spinal cord (SC). The expression of TRPV1-associated molecules such as pPKA, pERK, and pCREB was also increased in the thalamus and somatosensory cortex (SSC) of the mice. All the aforementioned mechanisms were reversed by EA treatment and TRPV1 gene deletion. Conclusion: Altogether, our results implied significant mechanisms of CFM and EA-analgesia that involve the regulation of the TRPV1 signaling pathway. These findings may be relevant to the evaluation and treatment of CFM.
https://ijbms.mums.ac.ir/article_15569_d1c5686a56d0de554848c4ffe9ef3f98.pdf
2020-07-01
894
900
10.22038/ijbms.2020.39708.9408
Dorsal root ganglion
Electroacupuncture
Fibromyalgia pain
pERK
Spinal Cord
TRPV1
Chia-Ming
Yen
terryyen1974@gmail.com
1
College of Chinese Medicine, Graduate Institute of Acupuncture Science, China Medical University, Taichung 40402, Taiwan
AUTHOR
Ching-Liang
Hsieh
clhsieh@mail.cmuh.edu.tw
2
College of Chinese Medicine, Graduate Institute of Integrated Medicine, China Medical University, Taichung 40402, Taiwan
AUTHOR
Yi-Wen
Lin
yiwenlin@mail.cmu.edu.tw
3
College of Chinese Medicine, Graduate Institute of Acupuncture Science, China Medical University, Taichung 40402, Taiwan
LEAD_AUTHOR
1. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369:448-457.
1
2. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009; 139:267-284.
2
3. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288:1765-1769.
3
4. Apkarian AV, Baliki MN, Geha PY. Towards a theory of chronic pain. Prog Neurobiol 2009; 87:81-97.
4
5. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413:203-210.
5
6. English B. Neural and psychosocial mechanisms of pain sensitivity in fibromyalgia. Pain Manag Nurs 2014; 15:530-538.
6
7. Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014; 311:1547-1555.
7
8. Sluka KA, Kalra A, Moore SA. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 2001; 24:37-46.
8
9. Yen LT, Hsieh CL, Hsu HC, Lin YW. Targeting ASIC3 for Relieving Mice Fibromyalgia Pain: Roles of Electroacupuncture, Opioid, and Adenosine. Sci Rep 2017; 7:46663-46677.
9
10. DeSantana JM, Sluka KA. Central mechanisms in the maintenance of chronic widespread noninflammatory muscle pain. Curr Pain Headache Rep 2008; 12:338-343.
10
11. Yang B, Yi G, Hong W, Bo C, Wang Z, Liu Y, et al. Efficacy of acupuncture on fibromyalgia syndrome: a meta-analysis. J Tradit Chin Med 2014; 34:381-391.
11
12. Stival RS, Cavalheiro PR, Stasiak CE, Galdino DT, Hoekstra BE, Schafranski MD. [Acupuncture in fibromyalgia: a randomized, controlled study addressing the immediate pain response]. Rev Bras Reumatol 2014; 54:431-436.
12
13. Moran MM. TRP Channels as Potential Drug Targets. Annu Rev Pharmacol Toxicol 2018; 58:309-330.
13
14. Moran MM, Szallasi A. Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field. Br J Pharmacol 2018; 175:2185-2203.
14
15. Christoph T, Kogel B, Schiene K, Peters T, Schroder W. Investigation of TRPV1 loss-of-function phenotypes in TRPV1 Leu206Stop mice generated by N-ethyl-N-nitrosourea mutagenesis. Biochem Biophys Res Commun 2018; 500:456-461.
15
16. Liao HY, Hsieh CL, Huang CP, Lin YW. Electroacupuncture attenuates induction of inflammatory pain by regulating opioid and adenosine pathways in mice. Sci Rep 2017; 7:15679-15687.
16
17. Luo H, Xu IS, Chen Y, Yang F, Yu L, Li GX, et al. Behavioral and electrophysiological evidence for the differential functions of TRPV1 at early and late stages of chronic inflammatory nociception in rats. Neurochem Res 2008; 33:2151-2158.
17
18. Goldman N, Chen M, Fujita T, Xu Q, Peng W, Liu W, et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci 2010; 13:883-888.
18
19. Han JS. Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies. Trends Neurosci 2003; 26:17-22.
19
20. Chang FC, Tsai HY, Yu MC, Yi PL, Lin JG. The central serotonergic system mediates the analgesic effect of electroacupuncture on ZUSANLI (ST36) acupoints. J Biomed Sci 2004; 11:179-185.
20
21. Lin YW, Hsieh CL. Electroacupuncture at Baihui acupoint (GV20) reverses behavior deficit and long-term potentiation through N-methyl-d-aspartate and transient receptor potential vanilloid subtype 1 receptors in middle cerebral artery occlusion rats. J Integr Neurosci 2010; 9:269-282.
21
22. Lu KW, Yang J, Hsieh CL, Hsu YC, Lin YW. Electroacupuncture restores spatial learning and downregulates phosphorylated N-methyl-D-aspartate receptors in a mouse model of Parkinson’s disease. Acupunct Med 2017; 35:133-141.
22
23. Lin YW, Hsieh CL. Auricular electroacupuncture reduced inflammation-related epilepsy accompanied by altered TRPA1, pPKCalpha, pPKCepsilon, and pERk1/2 signaling pathways in kainic acid-treated rats. Mediators Inflamm 2014; 2014:493480.
23
24. Lu KW, Hsu CK, Hsieh CL, Yang J, Lin YW. Probing the effects and mechanisms of electroacupuncture at ipsilateral or contralateral ST36-ST37 acupoints on CFA-induced inflammatory pain. Sci Rep 2016; 6:22123-22133.
24
25. Littlejohn G, Guymer E. Neurogenic inflammation in fibromyalgia. Semin Immunopathol 2018; 40:291-300.
25
26. Rodriguez-Pinto I, Agmon-Levin N, Howard A, Shoenfeld Y. Fibromyalgia and cytokines. Immunol Lett 2014; 161:200-203.
26
27. Generaal E, Vogelzangs N, Macfarlane GJ, Geenen R, Smit JH, Dekker J, et al. Basal inflammation and innate immune response in chronic multisite musculoskeletal pain. Pain 2014; 155:1605-1612.
27
28. Uceyler N, Hauser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 2011; 12:245.
28
29. Rea K, Dinan TG, Cryan JF. The microbiome: A key regulator of stress and neuroinflammation. Neurobiol Stress 2016; 4:23-33.
29
30. Edwards JG. TRPV1 in the central nervous system: synaptic plasticity, function, and pharmacological implications. Prog Drug Res 2014; 68:77-104.
30
31. Marrone MC, Morabito A, Giustizieri M, Chiurchiu V, Leuti A, Mattioli M, et al. TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice. Nat Commun 2017; 8:15292-15309.
31
32. Bair MJ, Wu J, Damush TM, Sutherland JM, Kroenke K. Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med 2008; 70:890-897.
32
33. Liedberg GM, Bjork M, Borsbo B. Self-reported nonrestorative sleep in fibromyalgia-relationship to impairments of body functions, personal function factors, and quality of life. J Pain Res 2015; 8:499-505.
33
34. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain 2007; 23:15-22.
34
35. Sawaddiruk P, Paiboonworachat S, Chattipakorn N, Chattipakorn SC. Alterations of brain activity in fibromyalgia patients. J Clin Neurosci 2017; 38:13-22.
35
36. Yuksel E, Naziroglu M, Sahin M, Cig B. Involvement of TRPM2 and TRPV1 channels on hyperalgesia, apoptosis and oxidative stress in rat fibromyalgia model: Protective role of selenium. Sci Rep 2017; 7:17543-17554.
36
37. Maciel LY, da Cruz KM, de Araujo AM, Silva ZM, Badaue-Passos D Jr, Santana-Filho VJ, et al. Electroacupuncture reduces hyperalgesia after injections of acidic saline in rats. Evid Based Complement Alternat Med 2014; 2014:485043-485056.
37
38. Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 2004; 108:237-247.
38
39. Strickland IT, Martindale JC, Woodhams PL, Reeve AJ, Chessell IP, McQueen DS. Changes in the expression of NaV1.7, NaV1.8 and NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. Eur J Pain 2008; 12:564-572.
39
40. Laird JM, Souslova V, Wood JN, Cervero F. Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice. J Neurosci 2002; 22:8352-8356.
40
41. Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A 2007; 104:8520-8525.
41
ORIGINAL_ARTICLE
Point-of-care detection of Escherichia coli O157:H7 in water using AuNPs-based aptasensor
Objective(s): Access to safe drinking and irrigation water has always been one of the major human concerns worldwide. Thus, rapid, sensitive, and inexpensive approaches for pathogenic bacteria detection, such as Escherichia coli O157:H7 (EHEC) that can induce important infectious diseases, are highly on demand. Materials and Methods: In this study, a sensitive aptamer-based AuNPs bioassay was developed that demonstrated its potential to detect EHEC. In the presence of the target bacterium, the specific adsorbed aptamer, leaves AuNPs surface and interacts with EHEC. The bare nanoparticles aggregate in the presence of NaCl and the color shifts from red to purple and blue depending on the bacterial concentration. Results: The proposed aptasensor exhibited a good linear response over a wide concentration range of 876 to 107 CFU/ml and was closely correlated with the line equation of “y=0.0094x+0.0006” (R2= 0.9861). It also showed a low detection limit (LOD) of 263 CFU/ml (Signal/Noise=3). No response was recorded in the presence of other tested bacterial strains including Listeria monocytogenes and Salmonella typhi, indicating the high selectivity of the aptasensor. Conclusion: This biosensor may be used as a smart device to screen water reservoirs and prevents the outbreak of EHEC-related life-threatening contagious diseases.
https://ijbms.mums.ac.ir/article_15597_df2d43f5c762737d776270cbfc2d5780.pdf
2020-07-01
901
908
10.22038/ijbms.2020.44016.10322
Aptamer
Aptasensor
AuNPs
Escherichia coli O157:H7
water
Vahid
Soheili
soheiliv@mums.ac.ir
1
Department of Pharmacology and Toxicology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
AUTHOR
Seyed Mohammad
Taghdisi
taghdisihm@mums.ac.ir
2
Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Khalil
Abnous
abnouskh@mums.ac.ir
3
Pharmaceutical Research Center, Pharmaceutical Technology Institute, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mohsen
Ebrahimi
mepharmd@yahoo.com
4
Department of Pharmacology and Toxicology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
1. Teng J, Yuan F, Ye Y, Zheng L, Yao L, Xue F, et al. Aptamer-based technologies in foodborne pathogen detection. Front Microbiol 2016; 7:1-11.
1
2. Amaya-González S, de-los-Santos-Álvarez N, Miranda-Ordieres AJ, Lobo-Castañón MJ. Aptamer-based analysis: A promising alternative for food safety control. Sensors (Basel) 2013; 13:16292-16311.
2
3. Zahedi Bialvaei A, Sheikhalizadeh V, Mojtahedi A, Irajian G. Epidemiological burden of Listeria monocytogenes in Iran. Iran J Basic Med Sci 2018; 21:770-780.
3
4. Singh G, Manohar M, Adegoke AA, Stenström TA, Shanker R. Novel aptamer-linked nanoconjugate approach for detection of waterborne bacterial pathogens: an update. J Nanopart Res 2017; 19.
4
5. WHO. Water sanitation hygiene: Water-related diseases. 2019; Web: https://www.who.int/water_sanitation_health/diseases-risks/diseases/diarrhoea/en/
5
6. Singh P, Gupta R, Sinha M, Kumar R, Bhalla V. MoS2 based digital response platform for aptamer based fluorescent detection of pathogens. Microchim Acta 2016; 183:1501-1506.
6
7. Wu W, Zhang J, Zheng M, Zhong Y, Yang J, Zhao Y, et al. An aptamer-based biosensor for colorimetric detection of Escherichia coli O157:H7. PLoS One 2012; 7:1-9.
7
8. Mirani ZA, Fatima A, Urooj S, Aziz M, Khan MN, Abbas T. Relationship of cell surface hydrophobicity with biofilm formation and growth rate: A study on Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli. Iran J Basic Med Sci 2018; 21:760-769.
8
9. Brosel-Oliu S, Ferreira R, Uria N, Abramova N, Gargallo R, Muñoz-Pascual FX, et al. Novel impedimetric aptasensor for label-free detection of Escherichia coli O157:H7. Sensor Actuat B-Chem 2018; 255:2988-2995.
9
10. Lee YJ, Han SR, Maeng JS, Cho YJ, Lee SW. In vitro selection of Escherichia coli O157:H7-specific RNA aptamer. Biochem Biophys Res Commun 2012; 417:414-420.
10
11. Chung J, Kang JS, Jurng JS, Jung JH, Kim BC. Fast and continuous microorganism detection using aptamer-conjugated fluorescent nanoparticles on an optofluidic platform. Biosens Bioelectron 2015; 67:303-308.
11
12. Li H, Ding X, Peng Z, Deng L, Wang D, Chen H, et al. Aptamer selection for the detection of Escherichia coli k88. Can J Microbiol 2011; 57:453-459.
12
13. Wu W, Zhao S, Mao Y, Fang Z, Lu X, Zeng L. A sensitive lateral flow biosensor for Escherichia coli O157: H7 detection based on aptamer mediated strand displacement amplification. Anal Chim Acta 2015; 861:62-68.
13
14. Liu K, Yan X, Mao B, Wang S, Deng L. Aptamer-based detection of Salmonella enteritidis using double signal amplification by Klenow fragment and dual fluorescence. Microchim Acta 2016; 183:643-649.
14
15. Davydova A, Vorobjeva M, Pyshnyi D, Altman S, Vlassov V, Venyaminova A. Aptamers against pathogenic microorganisms. Crit Rev Microbiol 2016; 42:847-865.
15
16. Duan N, Wu S, Dai S, Miao T, Chen J, Wang Z. Simultaneous detection of pathogenic bacteria using an aptamer based biosensor and dual fluorescence resonance energy transfer from quantum dots to carbon nanoparticles. Microchim Acta 2015; 182:917-923.
16
17. Sekhon SS, Kim SG, Lee SH, Jang A, Min J, Ahn JY, et al. Advances in pathogen-associated molecules detection using aptamer based biosensors. Mol Cell Toxicol 2013; 9:311-317.
17
18. Soheili V, Taghdisi SM, Hassanzadeh Khayyat M, Fazly Bazzaz BBS, Ramezani M, Abnous K. Colorimetric and ratiometric aggregation assay for streptomycin using gold nanoparticles and a new and highly specific aptamer. Microchim Acta 2016; 183:1687-1697.
18
19. Sheikhzadeh E, Chamsaz M, Turner APF, Jager EWH, Beni V. Label-free impedimetric biosensor for Salmonella Typhimurium detection based on poly [pyrrole-co-3-carboxyl-pyrrole] copolymer supported aptamer. Biosens Bioelectron 2016; 80:194-200.
19
20. Shahdordizadeh M, Taghdisi SM, Ansari N, Alebooye Langroodi F, Abnous K, Ramezani M. Aptamer based biosensors for detection of Staphylococcus aureus. Sensor Actuat B-Chem 2017; 241:619-635.
20
21. Bruno JG, Chanpong J. Methods of producing competitive aptamer fret reagents and assays. Google Patents; 2008.
21
22. Liu J, Lu Y. Preparation of aptamer-linked gold nanoparticle purple aggregates for colorimetric sensing of analytes. Nat Protoc 2006; 1:246-252.
22
23. Wei H, Li B, Li J, Wang E, Dong S. Simple and sensitive aptamer-based colorimetric sensing of protein using unmodified gold nanoparticle probes. Chem Commun (Camb) 2007; Sep 28:3735-3737.
23
24. Demirkol DO, Timur S. A sandwich-type assay based on quantum dot/aptamer bioconjugates for analysis of E. Coli O157:H7 in microtiter plate format. Int J Polym Mater Po 2016; 65:85-90.
24
25. Yildirim N, Long F, Gu AZ, editors. Aptamer based E. coli detection in waste waters by portable optical biosensor system. 40th Annual Northeast Bioengineering Conference (NEBEC); 2014.
25
26. Sassolas A, Blum LJ, Leca-Bouvier BD. Optical detection systems using immobilized aptamers. Biosens Bioelectron 2011; 26:3725-3736.
26
27. Hong KL, Sooter LJ. Single-stranded DNA aptamers against pathogens and toxins: identification and biosensing applications. Biomed Res Int 2015; 2015:1-31.
27
28. Yang L, Zhang X, Ye M, Jiang J, Yang R, Fu T, et al. Aptamer-conjugated nanomaterials and their applications. Adv Drug Deliv Rev 2011; 63:1361-1370.
28
29. Gopinath SCB, Lakshmipriya T, Awazu K. Colorimetric detection of controlled assembly and disassembly of aptamers on unmodified gold nanoparticles. Biosens Bioelectron 2014; 51:115-123.
29
30. Derbyshire N, White SJ, Bunka DHJ, Song L, Stead S, Tarbin J, et al. Toggled RNA aptamers against aminoglycosides allowing facile detection of antibiotics using gold nanoparticle assays. Anal Chem 2012; 84:6595-6602.
30
31. Li L, Li B, Qi Y, Jin Y. Label-free aptamer-based colorimetric detection of mercury ions in aqueous media using unmodified gold nanoparticles as colorimetric probe. Anal Bioanal Chem 2009; 393:2051-2057.
31
32. Tan L, Neoh KG, Kang ET, Choe WS, Su X. Affinity analysis of DNA aptamer-peptide interactions using gold nanoparticles. Anal Biochem 2012; 421:725-731.
32
33. Kim HS, Kim YJ, Chon JW, Kim DH, Yim JH, Kim H, et al. Two-stage label-free aptasensing platform for rapid detection of Cronobacter sakazakii in powdered infant formula. Sensor Actuat B-Chem 2017; 239:94-99.
33
34. Wu WH, Li M, Wang Y, Ouyang HX, Wang L, Li XC, et al. Aptasensors for rapid detection of Escherichia coli O157: H7 and Salmonella typhimurium. Nanoscale Res Lett 2012; 7:658-664.
34
35. Fatin MF, Rahim Ruslinda A, Gopinath SCB, Arshad MKM, Hashim U, Lakshmipriya T, et al. Co-ordinated split aptamer assembly and disassembly on gold nanoparticle for functional detection of HIV-1 tat. Process Biochem 2019; 79:32-39.
35
36. Mondal B, Ramlal S, Lavu PS, Bhavanashri N, Kingston J. Highly sensitive colorimetric biosensor for Staphylococcal enterotoxin B by a label-free aptamer and gold nanoparticles. Front Microbiol 2018; 9:1-8.
36
37. Luan Y, Chen Z, Xie G, Chen J, Lu A, Li C, et al. Rapid visual detection of aflatoxin B1 by label-free aptasensor using unmodified gold nanoparticles. J Nanosci Nanotechnol 2015; 15: 1357-1361.
37
38. Yang C, Wang Y, Marty JL, Yang X. Aptamer-based colorimetric biosensing of Ochratoxin A using unmodified gold nanoparticles indicator. Biosens Bioelectron 2011; 26:2724-2727.
38
39. Shahrokhian S, Ranjbar S. Aptamer immobilization on amino-functionalized metal-organic frameworks: An ultrasensitive platform for the electrochemical diagnostic of Escherichia coli O157:H7. Analyst 2018; 143:3191-3201.
39
40. Yu X, Chen F, Wang R, Li Y. Whole-bacterium SELEX of DNA aptamers for rapid detection of E.coli O157:H7 using a QCM sensor. J Biotechnol 2018; 266:39-49.
40
41. Khang J, Kim D, Chung KW, Lee JH. Chemiluminescent aptasensor capable of rapidly quantifying Escherichia coli O157:H7. Talanta 2016; 147:177-183.
41
42. Renuka RM, Achuth J, Chandan HR, Venkataramana M, Kadirvelu K. A fluorescent dual aptasensor for the rapid and sensitive onsite detection of E. coli O157:H7 and its validation in various food matrices. New J Chem 2018; 42:10807-10817.
42
43. Wang Q, Long M, Lv C, Xin S, Han X, Jiang W. Lanthanide-labeled fluorescent-nanoparticle immunochromatographic strips enable rapid and quantitative detection of Escherichia coli O157:H7 in food samples. Food Control 2020; 109:106894-106903.
43
44. Bu SJ, Wang KY, Bai HS, Leng Y, Ju CJ, Wang CY, et al. Immunoassay for pathogenic bacteria using platinum nanoparticles and a hand-held hydrogen detector as transducer. Application to the detection of Escherichia coli O157:H7. Microchim Acta 2019; 186:296-302.
44
45. Mo X, Wu Z, Huang J, Zhao G, Dou W. A sensitive and regenerative electrochemical immunosensor for quantitative detection of Escherichia coli O157:H7 based on stable polyaniline coated screen-printed carbon electrode and rGO-NR-Au@Pt. Anal Methods 2019; 11:1475-1482.
45
46. Kim TH, Hwang HJ, Kim JH. Ultra-fast on-site molecular detection of foodborne pathogens using a combination of convection polymerase chain reaction and nucleic acid lateral flow immunoassay. Foodborne Pathog Dis 2019; 16:144-151.
46
47. Zhu C, Zhao G, Dou W. Core-shell red silica nanoparticles based immunochromatographic assay for detection of Escherichia coli O157:H7. Anal Chim Acta 2018; 1038:97-104.
47
48. Mo X, Zhao G, Dou W. Electropolymerization of stable leucoemeraldine base polyaniline film and application for quantitative detection of Escherichia coli O157:H7. J Electro Mater 2018; 47:6507-6517.
48
49. Hu J, Huang R, Wang Y, Wei X, Wang Z, Geng Y, et al. Development of duplex PCR-ELISA for simultaneous detection of Salmonella spp. and Escherichia coli O157: H7 in food. J Microbiol Methods 2018; 154:127-133.
49
50. Pang B, Zhao C, Li L, Song X, Xu K, Wang J, et al. Development of a low-cost paper-based ELISA method for rapid Escherichia coli O157:H7 detection. Anal Biochem 2018; 542:58-62.
50
51. Jin SA, Heo Y, Lin LK, Deering AJ, Chiu GTC, Allebach JP, et al. Gold decorated polystyrene particles for lateral flow immunodetection of Escherichia coli O157:H7. Microchim Acta 2017; 184:4879-4886.
51
52. Guo Q, Han JJ, Shan S, Liu DF, Wu SS, Xiong YH, et al. DNA-based hybridization chain reaction and biotin–streptavidin signal amplification for sensitive detection of Escherichia coli O157:H7 through ELISA. Biosens Bioelectron 2016; 86:990-995.
52
53. Tian F, Lyu J, Shi J, Tan F, Yang M. A polymeric microfluidic device integrated with nanoporous alumina membranes for simultaneous detection of multiple foodborne pathogens. Sensor Actuat B-Chem 2016; 225:312-318.
53
54. Hassan ARHAA, de la Escosura-Muñiz A, Merkoçi A. Highly sensitive and rapid determination of Escherichia coli O157: H7 in minced beef and water using electrocatalytic gold nanoparticle tags. Biosens Bioelectron 2015; 67:511-515.
54
55. Cho IH, Mauer L, Irudayaraj J. In-situ fluorescent immunomagnetic multiplex detection of foodborne pathogens in very low numbers. Biosens Bioelectron 2014; 57:143-148.
55
56. Song C, Li J, Liu J, Liu Q. Simple sensitive rapid detection of Escherichia coli O157:H7 in food samples by label-free immunofluorescence strip sensor. Talanta 2016; 156-157:42-47.
56
57. Yacoub-George E, Hell W, Meixner L, Wenninger F, Bock K, Lindner P, et al. Automated 10-channel capillary chip immunodetector for biological agents detection. Biosens Bioelectron 2007; 22:1368-1375.
57
58. Liu X, Li RZ, Li L, Li WJ, Zhou CJ. Immunoanalysis of E. coli O157:H7 based on Au nanoparticles labelling antibody using SPR biosensor. Chem J Chinese U 2013; 34:1333-1338.
58
59. Liu Y, Cao Y, Wang T, Dong Q, Li J, Niu C. Detection of 12 common food-borne bacterial pathogens by taq man real-time PCR using a single set of reaction conditions. Front Microbiol 2019; 10:1-9.
59
ORIGINAL_ARTICLE
A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses
Objective(s): Infection with tuberculosis (TB) is regarded as a major health issue. Due to the emergence of antibiotic resistance during TB treatment, prevention via vaccination is one of the most effective ways of controlling the infection. DNA vaccines are developed at a greater pace due to their ability in generating a long-lasting immune response, higher safety compared to the live vaccines, and relatively lower cost of production. In the present study, we evaluated a new DNA vaccine encoding the fusion HspX-PPE44-EsxV antigens, separately, and in combination with Bacillus Calmette–Guérin (BCG) administration, in a prime-boost method in mice.Materials and Methods: A novel DNA vaccine encoding HspX-PPE44-EsxV fusion antigen of Mycobacterium tuberculosis was constructed, and RT-PCR and Western blot analysis were performed to verify the expression of the antigen. Female BALB/c mice were divided into five groups (PBS, BCG, pcDNA3.1 (+) vector, pDNA/HspX-PPE44-EsxV vaccine, and the BCG-prime boost groups). In order to evaluate the immunogenicity of the recombinant vector, BALB/c mice were injected with 100 μg of pDNA at 2-week intervals. Then, cytokine assay was conducted using eBioscience ELISA kits (Ebioscience, AUT) according to manufacturers’ instructions to evaluate the concentrations of IL-4, IL-12, TGF-β, and IFN-γ.Results: The concentrations of INF-γ, IL-12, and TGF-beta were significantly increased compared to the control groups (P<0.001). INF-γ and IL-12 production were increased significantly in pDNA/HspX-PPE44-EsxV+BCG group compared to pDNA/HspX-PPE44-EsxV group (P<0.001).Conclusion: This study showed that the present DNA vaccine could induce a high level of specific cytokines in mice. It was also shown that using this DNA vaccine in a BCG prime-boost protocol can produce significant amounts of IFN-γ, IL-12, and TGF-β.
https://ijbms.mums.ac.ir/article_15571_2f7a631adf8413ee1bc9ce23ef142c9f.pdf
2020-07-01
909
914
10.22038/ijbms.2020.38521.9171
BCG
DNA
Mycobacterium tuberculosis PCR
Vaccine
Bagher
Moradi
moradib901@gmail.com
1
Esfarayen Faculty of Medical Sciences, Esfarayen, Iran
AUTHOR
Mojtaba
Sankian
sankianm@mums.ac.ir
2
Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Yousef
Amini
yousefamini1363@gmail.com
3
Infectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran
AUTHOR
Aida
Gholoobi
gholoubiad@mums.ac.ir
4
Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Zahra
Meshkat
meshkatz@mums.ac.ir
5
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Daniel TM. The history of tuberculosis. Respir Med 2006; 100:1862-1870.
1
2. Dara M, Dadu A, Kremer K, Zaleskis R, Kluge HH. Epidemiology of tuberculosis in WHO European region and public health response Eur Spine J 2013; 22:549-555.
2
3. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 2010; 328:856-861.
3
4. Moradi B, Meshkat Z. Evaluation of tuberculosis infection in pregnant women and its effects on newborns: an overview. Iran J Obstet Gynecol 2015; 18:21-36.
4
5. Barreto ML, Pilger D, Pereira SM, Genser B, Cruz AA, Cunha SS, et al. Causes of variation in BCG vaccine efficacy: examining evidence from the BCG REVAC cluster randomized trial to explore the masking and the blocking hypotheses. Vaccine 2014; 32:3759-3764.
5
6. Kaufmann SH, Hussey G, Lambert P-H. New vaccines for tuberculosis. Lancet 2010; 375:2110-2119.
6
7. Parida SK, Kaufmann SH. Novel tuberculosis vaccines on the horizon. Curr Opin Immunol 2010; 22:374-384.
7
8. Delogu G, Fadda G. The quest for a new vaccine against tuberculosis. J Infect Dev Ctries 2009; 3: 5-15.
8
9. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Eddine AN, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J clin Invest 2005; 115:2472-2479.
9
10. Saltzman MW, Shen H, Brandsma JL. DNA vaccines: methods and protocols: Springer Science & Business Media; 2006.
10
11. Mustafa AS. In silico analysis and experimental validation of Mycobacterium tuberculosis-specific proteins and peptides of Mycobacterium tuberculosis for immunological diagnosis and vaccine development. Med Prin Pract 2013; 22:43-51.
11
12. Junqueira-Kipnis AP, Neto M, Moreira L, Kipnis A. Role of fused Mycobacterium tuberculosis immunogens and adjuvants in modern tuberculosis vaccines. Front Immunol 2014; 5:188.
12
13. Amini Y, Moradi B, Tafaghodi M, Meshkat Z, Ghazvini K, Fasihi-Ramandi M. TB trifusion antigen adsorbed on calcium phosphate nanoparticles stimulates strong cellular immunity in mice. Biotechnol Bioproc E 2016; 21:653-658.
13
14. Dubaniewicz A, Holownia A, Kalinowski L, Wybieralska M, Dobrucki IT, Singh M. Is mycobacterial heat shock protein 16 kDa, a marker of the dormant stage of Mycobacterium tuberculosis, a sarcoid antigen. Hum immunol 2013; 74:45-51.
14
15. Yuan W, Dong N, Zhang L, Liu J, Lin S, Xiang Z, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice. Vaccine 2012; 14:2490-2497.
15
16. Shi C, Chen L, Chen Z, Zhang Y, Zhou Z, Lu J, et al. Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein. Vaccine 2010; 28:5237-5244.
16
17. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 2006; 13:179-186.
17
18. Bruffaerts N, Romano M, Denis O, Jurion F, Huygen K. Increasing the vaccine potential of live M. bovis BCG by coadministration with plasmid DNA encoding a tuberculosis prototype antigen. Vaccines 2014; 2:181-195.
18
19. Romano M, Rindi L, Korf H, Bonanni D, Adnet P-Y, Jurion F, et al. Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c). Vaccine 2008; 26:6053-6063.
19
20. Abdallah AM, Savage ND, van Zon M, Wilson L, Vandenbroucke-Grauls CM, van der Wel NN, et al. The ESX-5 secretion system of Mycobacterium marinum modulates the macrophage response. J Immunol 2008; 181:7166-7175.
20
21. Villarreal DO, Walters J, Laddy DJ, Yan J, Weiner DB. Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG. Hum Vaccin immunother 2014; 10:2188-2198.
21
22. Wang C, Chen Z, Fu R, Zhang Y, Chen L, Huang L, et al. A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice. Med Microbiol Immunol 2011; 200:165-175.
22
23. Derrick SC, Repique C, Snoy P, Yang AL, Morris S. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect immun 2004; 72:1685-1692.
23
24. Okada M, Kita Y, Nakajima T, Hashimoto S, Nakatani H, Nishimatsu S, et al. The study of novel DNA vaccines against tuberculosis: Induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis. Hum Vaccin Immunother 2013; 9:515-525.
24
25. Moradi B, Sankian M, Amini Y, Meshkat Z. Construction of a novel DNA vaccine candidate encoding an HspX-PPE44-EsxV fusion antigen of Mycobacterium tuberculosis. Rep Biochem Mol Biol 2016; 4:89.
25
26. Meshkat Z, Rashidian S, Arzanlou M, Teimourpour R. Immunogenicity of a DNA Vaccine Encoding Ag85a-Tb10. 4 antigens from mycobacterium tuberculosis. Iran J Immunol 2016; :289.
26
27. Henshaw J MB, Yuan F. Enhancement of electric field-mediated gene delivery through pretreatment of tumors with a hyperosmotic mannitol solution. Cancer Gene Ther 2011; 18:26-33.
27
28. Amini Y, Tafaghodi M, Jamehdar SA, Meshkat Z, Moradi B, Sankian M. Heterologous expression, purification, and characterization of the HspX, Ppe44, and EsxV proteins of Mycobacterium tuberculosis. Rep Biochem Mol Biol 2018; 6:125.
28
29. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-1180.
29
30. Gu D, Chen W, Mi Y, Gong X, Luo T, Bao L. The Mycobacterium bovis BCG prime-Rv0577 DNA boost vaccination induces a durable Th1 immune response in mice. Acta Biochim Biophys Sin 2016; 48:385-390.
30
31. Lichty B, Bridle B, Wan Y, Bramson J. Vaccination methods. Google Patents; 2017.
31
32. Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL, et al. Immunogenicity of eight dormancy (DosR) regulon encoded proteins of Mycobacterium tuberculosis in DNA vaccinated and TB infected mice. Infect Immun 2007; 75:941-949.
32
33. Aguilo N, Gonzalo-Asensio J, Alvarez-Arguedas S, Marinova D, Gomez AB, Uranga S, et al. Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis. Nat Commun 2017;8:1-11
33
34. Yuan W, Dong N, Zhang L, Liu J, Lin S, Xiang Z, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice. Vaccine 2012; 30:2490-2497.
34
35. Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL, et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect immun 2007; 75:941-949.
35
36. Dey B, Jain R, Khera A, Gupta UD, Katoch V, Ramanathan V, et al. Latency antigen α-crystallin based vaccination imparts a robust protection against TB by modulating the dynamics of pulmonary cytokines. PLoS One 2011; 6: e18773.
36
37. Khan TA, Mazhar H, Saleha S, Tipu HN, Muhammad N, Abbas MN. Interferon-gamma improves macrophages function against M. tuberculosis in multidrug-resistant tuberculosis patients. Chemother Res Pract 2016.
37
38. Domingo-Gonzalez R, Prince O, Cooper A, Khader S. Cytokines and chemokines in Mycobacterium tuberculosis infection. Chemother Res Pract 2017:33-72.
38
39. Blomgran R, Ernst JD. Lung neutrophils facilitate activation of naive antigen-specific CD4+ T cells during Mycobacterium tuberculosis infection. J Immunol 2011; 186:7110-7119.
39
40. Von Garnier C, Nicod LP. Immunology taught by lung dendritic cells. Swiss Med Wkly 2009; 139:186-192.
40
41. Etna MP, Giacomini E, Severa M, Coccia EM, editors. Pro-and anti-inflammatory cytokines in tuberculosis: a two-edged sword in TB pathogenesis. Semin Immunol 2014; 26: 543-551.
41
42. Mayer-Barber KD, Sher A. Cytokine and lipid mediator networks in tuberculosis. Immunol Rev 2015; 264:264-275.
42
ORIGINAL_ARTICLE
Genotypic and phenotypic characterization of enteroaggregative Escherichia coli (EAEC) isolates from diarrheic children: An unresolved diagnostic paradigm exists
Objective(s): The enteroaggregative Escherichia coli (EAEC) has been one of the most intriguing emerging bacterial pathogens in children that occur both in developing countries and the industrial world. Although various phenotypic and genotypic based protocols have been suggested for diagnosis of EAEC, they are not conclusive or practical to be used in most clinical laboratories. Materials and Methods: In this study, we analyzed and compared 36 typical EAEC strains (aggR-positive) by various genotypic and phenotypic methods.Results: Briefly, pCVD432 was detected in all of isolates along with aggR, then it was followed by other virulence genes including app, astA, aggA, and pet genes in 32 (88.8%), 21 (58.3%), 9 (25%), and 2 (5.5%) isolates, respectively. Biofilm was formed by 34 (94.4%) isolates, while only 26 (72.2%) isolates showed an aggregative adherence pattern to HEp-2 cells. Conclusion: The genetic and phenotypic features of EAEC were highly inconsistent, which may have considerable diagnostic implications. The variations in the virulence genes, phenotypic characteristics, and genetic profiles among the EAEC isolates again emphasized the genetic heterogeneity of this emerging pathotype. Biofilm formation may be an important phenotypic virulence property of this pathotype, especially in strains with the aggR-pCVD432-aap-astA profile.
https://ijbms.mums.ac.ir/article_15495_dc171ed7b6d0a6403e6ee68248d0ee9a.pdf
2020-07-01
915
921
10.22038/ijbms.2020.42119.9959
Aggregative adherence
Biofilm
Diagnosis
Diarrhea
Enteroaggregative-Escherichia coli
Virulence genes
Haiffa
Helalat
haifa_helalat@hotmail.com
1
Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
AUTHOR
Seyedeh Elham
Rezatofighi
e.tofighi@yahoo.com
2
Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
LEAD_AUTHOR
Mohammad
Roayaei Ardakani
m.roayaei@scu.ac.ir
3
Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
AUTHOR
Luis Fernando
Dos Santos
luisfernando.lfs@uol.com.br
4
Adolfo Lutz Institute, Centere of Bacteriology, National Reference Laboratory for E. coli enteric infections and HUS. São Paulo, Brazil
AUTHOR
Mahdi
Askari Badouei
askari.m@um.ac.ir
5
Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
AUTHOR
1. Sukkua K, Patungkaro W, Sukhumungoon P. Detection and molecular characterization of enteroaggregative Escherichia coli from diarrheal patients in tertiary hospitals, southern Thailand. Southeast Asian J Trop Med Public Health 2015;46:901-910.
1
2. Haghi F, Zeighami H, Hajiahmadi F, Khoshvaght H, Bayat M. Frequency and antimicrobial resistance of diarrhoeagenic Escherichia coli from young children in Iran. J Med Microbiol 2014;63:427-432.
2
3. Kubomura A, Misaki T, Homma S, Matsuo C, Okabe N. Phenotypic and molecular characterization of enteroaggregative Escherichia coli isolated in Kawasaki, Japan. Jpn J Infect Dis 2017;70:507-512.
3
4. Harrington SM, Dudley EG, Nataro JP. Pathogenesis of enteroaggregative Escherichia coli infection. FEMS Microbiol Lett 2006;254:12-18.
4
5. Nataro JP, Steiner T, Guerrant RL. Enteroaggregative Escherichia coli. Emerg Infect Dis 1998;4:251-261.
5
6. Franca FL, Wells TJ, Browning DF, Nogueira RT, Sarges FS, Pereira AC, et al. Genotypic and phenotypic characterisation of enteroaggregative Escherichia coli from children in Rio de Janeiro, Brazil. PLoS One 2013;8:e69971.
6
7. Brzuszkiewicz E, Thurmer A, Schuldes J, Leimbach A, Liesegang H, Meyer FD, et al. Genome sequence analyses of two isolates from the recent Escherichia coli outbreak in Germany reveal the emergence of a new pathotype: Entero-Aggregative-Haemorrhagic Escherichia coli (EAHEC). Arch Microbiol 2011;193:883-891.
7
8. Cerna JF, Nataro JP, Estrada-Garcia T. Multiplex PCR for detection of three plasmid-borne genes of enteroaggregative Escherichia coli strains. J Clin Microbiol 2003;41:2138-2140.
8
9. Hebbelstrup Jensen B, Poulsen A, Hebbelstrup Rye Rasmussen S, Struve C, Engberg JH, Friis-Møller A, et al. Genetic virulence profile of enteroaggregative Escherichia coli strains isolated from danish children with either acute or persistent diarrhea. Front Cell Infect Microbiol 2017;7:230.
9
10. Estrada-Garcia T, Perez-Martinez I, Bernal-Reynaga R, Zaidi MB. Enteroaggregative Escherichia coli: a pathogen bridging the north and south. Curr Trop Med Rep 2014;1:88-96.
10
11. Hebbelstrup Jensen B, Olsen KE, Struve C, Krogfelt KA, Petersen AM. Epidemiology and clinical manifestations of enteroaggregative Escherichia coli. Clin Microbiol Rev 2014;27:614-630.
11
12. Kahali S, Sarkar B, Rajendran K, Khanam J, Yamasaki S, Nandy RK, et al. Virulence characteristics and molecular epidemiology of enteroaggregative Escherichia coli isolates from hospitalized diarrheal patients in Kolkata, India. J Clin Microbiol 2004;42:4111-4120.
12
13. Jonsson R, Struve C, Boisen N, Mateiu RV, Santiago AE, Jenssen H, et al. Novel aggregative adherence fimbria variant of enteroaggregative Escherichia coli. Infect Immun 2015;83:1396-1405.
13
14. Shamir ER, Warthan M, Brown SP, Nataro JP, Guerrant RL, Hoffman PS. Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae. Antimicrob Agents Chemother 2010;54:1526-1533.
14
15. Boisen N, Struve C, Scheutz F, Nataro JP. New adhesin of enteroaggregative Escherichia coli related to the Afa/Dr/AAF family. Infect Immun 2008;76:3281-3292.
15
16. Czeczulin JR, Balepur S, Hicks S, Phillips A, Hall R, Kothary MH, et al. Aggregative adherence fimbria II, a second fimbrial antigen mediating aggregative adherence in enteroaggregative Escherichia coli. Infect Immun 1997;65:4135-4145.
16
17. Vijay D, Dhaka P, Vergis J, Negi M, Mohan V, Kumar M, et al. Characterization and biofilm forming ability of diarrhoeagenic enteroaggregative Escherichia coli isolates recovered from human infants and young animals. Comp Immunol Microbiol Infect Dis 2015;38:21-31.
17
18. Chattaway MA, Harris R, Jenkins C, Tam C, Coia JE, Gray J, et al. Investigating the link between the presence of enteroaggregative Escherichia coli and infectious intestinal disease in the United Kingdom, 1993 to 1996 and 2008 to 2009. Euro Surveill 2013;18:1-7.
18
19. Nataro JP, Mai V, Johnson J, Blackwelder WC, Heimer R, Tirrell S, et al. Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and New Haven, Connecticut. Clin Infect Dis 2006;43:402-407.
19
20. Bueris V, Sircili MP, Taddei CR, dos Santos MF, Franzolin MR, Martinez MB, et al. Detection of diarrheagenic Escherichia coli from children with and without diarrhea in Salvador, Bahia, Brazil. Memórias do Instituto Oswaldo Cruz 2007;102:839-844.
20
21. Hegde A, Ballal M, Shenoy S. Detection of diarrheagenic Escherichia coli by multiplex PCR. Indian J Med Microbiol 2012;30:279-84.
21
22. Jafari A, Aslani MM, Bouzari S. Escherichia coli: a brief review of diarrheagenic pathotypes and their role in diarrheal diseases in Iran. Iran J Microbiol 2012;4:102-117.
22
23. Mahdavi Broujerdi S, Roayaei Ardakani M, Rezatofighi SE. Characterization of diarrheagenic Escherichia coli strains associated with diarrhea in children, Khouzestan, Iran. J Infect Dev Ctries 2018;12:649-656
23
24. Mohamed JA, Huang DB, Jiang ZD, DuPont HL, Nataro JP, Belkind-Gerson J, et al. Association of putative enteroaggregative Escherichia coli virulence genes and biofilm production in isolates from travelers to developing countries. J Clin Microbiol 2007;45:121-126.
24
25. Muller D, Greune L, Heusipp G, Karch H, Fruth A, Tschäpe H, et al. Identification of unconventional intestinal pathogenic Escherichia coli isolates expressing intermediate virulence factor profiles by using a novel single-step multiplex PCR. Appl Environ Microbiol 2007;73:3380-3390.
25
26. Schmidt H, Knop C, Franke S, Aleksic S, Heesemann J, Karch H. Development of PCR for screening of enteroaggregative Escherichia coli. J Clin Microbiol 1995;33:701-705.
26
27. Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 1991;19:6823-6831.
27
28. Weigel RM, Qiao B, Teferedegne B, Suh DK, Barber DA, Isaacson RE, et al. Comparison of pulsed field gel electrophoresis and repetitive sequence polymerase chain reaction as genotyping methods for detection of genetic diversity and inferring transmission of Salmonella. Vet Microbiol 2004;100:205-217.
28
29. Pereira AC, Britto-Filho JD, Jose de Carvalho J, de Luna Md, Rosa AC. Enteroaggregative Escherichia coli (EAEC) strains enter and survive within cultured intestinal epithelial cells. Microb Pathog 2008;45:310-314.
29
30. Okhuysen PC, Dupont HL. Enteroaggregative Escherichia coli (EAEC): a cause of acute and persistent diarrhea of worldwide importance. J Infect Dis 2010;202:503-505.
30
31. Bafandeh S, Haghi F, Zeighami H. Prevalence and virulence characteristics of enteroaggregative Escherichia coli in a case-control study among patients from Iran. J Med Microbiol 2015;64:519-524.
31
32. Estrada-Garcia T, Navarro-Garcia F. Enteroaggregative Escherichia coli pathotype: a genetically heterogeneous emerging foodborne enteropathogen. FEMS Immunol Med Microbiol 2012;66:281-298.
32
33. Jenkins C. Enteroaggregative Escherichia coli. Curr Top Microbiol Immunol 2018; 416:27-50.
33
34. Gupta D, Sharma M, Sarkar S, Thapa BR, Chakraborti A. Virulence determinants in enteroaggregative Escherichia coli from North India and their interaction in in vitro organ culture system. FEMS Microbiol Lett 2016;363:1-7.
34
35. Vila J, Vargas M, Henderson IR, Gascón J, Nataro JP. Enteroaggregative Escherichia coli virulence factors in traveler’s diarrhea strains. J Infect Dis 2000;182:1780-1783.
35
36. Okeke IN, Lamikanra A, Czeczulin J, Dubovsky F, Kaper JB, Nataro JP. Heterogeneous virulence of enteroaggregative Escherichia coli strains isolated from children in Southwest Nigeria. J Infect Dis 2000;181:252-260.
36
37. Mendez-Arancibia E, Vargas M, Soto S, Ruiz J, Kahigwa E, Schellenberg D, et al. Prevalence of different virulence factors and biofilm production in enteroaggregative Escherichia coli isolates causing diarrhea in children in Ifakara (Tanzania). Am J of Trop Med Hyg 2008;78:985-989.
37
38. Okeke IN, Lamikanra A, Steinruck H, Kaper JB. Characterization of Escherichia coli strains from cases of childhood diarrhea in provincial southwestern Nigeria. J Clin Microbiol 2000;38:7-12.
38
39. Aslani MM, Alikhani MY, Zavari A, Yousefi R, Zamani AR. Characterization of enteroaggregative Escherichia coli (EAEC) clinical isolates and their antibiotic resistance pattern. Int J Infect Dis 2011;15:e136-139.
39
40. Davoodabadi A, Abbaszadeh M, Oloomi M, Bouzari S. Phenotypic and genotypic characterization of enteroaggregative Escherichia coli strains isolated from diarrheic children in Iran. Jundishapur J Microbiol 2015;8:e22295.
40
41. Askari Badouei M, Jajarmi M, Mirsalehian A. Virulence profiling and genetic relatedness of shiga toxin-producing Escherichia coli isolated from humans and ruminants. Comp Immunol Microbiol and Infect Dis 2015;38:15-20.
41
ORIGINAL_ARTICLE
Preparation and characterization of bear bile-loaded pH sensitive in-situ gel eye drops for ocular drug delivery
Objective(s): In this study, a stable bear bile-loaded pH sensitive in-situ eye drop gel was prepared for sustain delivery and enhanced therapeutic application. Materials and Methods: Bear bile-loaded in-situ ocular gels with different Carbopol/Hydroxypropyl methylcellulose (HPMC) ratios were prepared and their stability was tested in PBS at a series of pH at 40 °C. The morphology was observed by SEM examination and rheology was observed by Rheometer equipped with a 60-mm cone-plate at apex angle of 1°. Gel erosion and release kinetics of Tauroursodeoxycholic acid (TUDCA) was determined by HPLC. While, the in vivo dwelling time was obtained after administering the fluorescent-loaded gel in ocular disease-free New Zealand rabbits. Finally, biocompatibility and toxicity was observed by irritation test and H&E staining of eye-ball tissues, respectively. Results: The bear bile-loaded in-situ ocular gel showed excellent stability at different pH (pH 5.0, 5.5, 6.0, 6.5, 7.0 and 8.0) up to 5 days, and bear bile extract significantly attenuated the gelling ability of the in-situ gel. The viscosity of in-situ gels formulation was decreased with increase in shear rate (0.01 to 100 s-1), and morphological examination of freeze-dried preparation showed three-dimensional reticular structure at physiological pH. The in-situ ocular gel exhibited promising sustained drug release up to 160 min in vitro, and showed prolonged retention time up to 3-folds in vivo. Finally, the biocompability data confirmed that the formulation did not induce any toxic effects and was completely compatible with eye tissues.Conclusion: pH sensitive in-situ ocular gel provides new research opportunities to efficiently treat eye diseases.
https://ijbms.mums.ac.ir/article_15651_fa322eeba02bc0c6df2e63b57614e02a.pdf
2020-07-01
922
929
10.22038/ijbms.2020.45386.10562
Bear bile
In-situ ocular gel
pH sensitive
Rheology
Sustain-releas
Xiaomin
Ni
1
School of Pharmaceutical Sciences, Sun Yat-sen University, University Town, Guangzhou 510006, PR China
AUTHOR
Qin
Guo
2
School of Pharmaceutical Sciences, Sun Yat-sen University, University Town, Guangzhou 510006, PR China
AUTHOR
Yiqing
Zou
3
School of Pharmaceutical Sciences, Sun Yat-sen University, University Town, Guangzhou 510006, PR China
AUTHOR
Yang
Xuan
4
School of Pharmaceutical Sciences, Sun Yat-sen University, University Town, Guangzhou 510006, PR China
AUTHOR
Imran Shair
Mohammad
shair@mail.sysu.edu.cn
5
School of Pharmaceutical Sciences, Sun Yat-sen University, University Town, Guangzhou 510006, PR China
LEAD_AUTHOR
Qing
Ding
6
Yunnan Dai Medicine Co., Ltd., Yunnan 678699, PR China
AUTHOR
Haiyan
Hu
7
School of Pharmaceutical Sciences, Sun Yat-sen University, University Town, Guangzhou 510006, PR China
AUTHOR
1. Järvinen K, Järvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Rev 1995;16:3-19.
1
2. Janagam DR, Wu L, Lowe TL. Nanoparticles for drug delivery to the anterior segment of the eye. Adv Drug Deliv Rev 2017; 122:31-64.
2
3. Weng Y, Liu J, Jin S, Guo W, Liang X, Hu Z. Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm Sin B 2017; 7:281-291.
3
4. Huang M, Song J, Lu B, Huang H, Chen Y, Yin W, et al. Synthesis of taurine–fluorescein conjugate and evaluation of its retina-targeted efficiency in vitro. Acta Pharm Sin B 2014; 4:447-453.
4
5. He Zx, Wang Zh, Zhang Hh, Pan X, Su Wr, Liang D. Doxycycline and hydroxypropyl-β cyclodextrin complex in poloxamer thermal sensitive hydrogel for ophthalmic delivery. Acta Pharm Sin B 2011; 1:254-260
5
6. Yu S, Wang Q-M, Wang X, Liu D, Zhang W, Ye T, et al. Liposome incorporated ion sensitive in situ gels for opthalmic delivery of timolol maleate. Int J Pharm 2015; 480:128-136.
6
7. Jaiswal M, Kumar M, Pathak K. Zero order delivery of itraconazole via polymeric micelles incorporated in situ ocular gel for the management of fungal keratitis. Colloids Surf B Biointerfaces 2015; 130:23-30.
7
8. He W, Guo X, Feng M, Mao N. In vitro and in vivo studies on ocular vitamin A palmitate cationic liposomal in situ gels. Int J Pharm 2013; 458:305-314.
8
9. Agrawal AK, Das M, Jain S. In situ gel systems as ‘smart’carriers for sustained ocular drug delivery. Expert Opin Drug Deliv 2012; 9:383-402.
9
10. Kotreka UK, Davis VL, Adeyeye MC. Development of topical ophthalmic in situ gel-forming estradiol delivery system intended for the prevention of age-related cataracts. PloS One 2017; 12:e0172306.
10
11. Gupta H, Aqil M, Khar R, Ali A, Bhatnagar A, Mittal G. An alternative in situ gel-formulation of levofloxacin eye drops for prolong ocular retention. J Pharm Bioallied Sci 2015; 7:9-14.
11
12. Duan Y, Cai X, Du H, Zhai G. Novel in situ gel systems based on P123/TPGS mixed micelles and gellan gum for ophthalmic delivery of curcumin. Colloid Surf B Biointerfaces 2015; 128:322-330.
12
13. Appiah S, Revitt M, Jones H, Vu M, Simmonds M, Bell C. Anti-inflammatory and hepatoprotective medicinal herbs as potential substitutes for bear bile. Int Rev Neurobiology 2017; 135:149-180.
13
14. Chen Hw, Shen Al, Liu Ly, Peng J, Chu Jf. Bear bile powder inhibits growth of hepatocellular carcinoma via suppressing STAT3 signaling pathway in mice. Chin J Integr Med 2020;26:370-374.
14
15. Boatright JH, Nickerson JM, Moring AG, Pardue MT. Bile acids in treatment of ocular disease. J Ocul Biol Dis Infor 2009; 2:149-159.
15
16. Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med 2014; 3:58-69.
16
17. Li Y, Zhang X, Wang J, Sellers JT, Boyd AP, Nickerson JM, et al. Effect of systemic treatment with Tauroursodeoxycholic Acid (TUDCA) on retinal ganglion cell death following optic nerve crush. BioRxiv 2019; 733568.
17
18. Mandal S, Thimmasetty MK, Prabhushankar G, Geetha M. Formulation and evaluation of an in situ gel-forming ophthalmic formulation of moxifloxacin hydrochloride. Int J Pharm Investigat 2012; 2:78-82.
18
19. Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther.1944; 82:377-390.
19
20. Luo Q, Chen Q, Wu Y, Jiang M, Chen Z, Zhang X, et al. [Chemical constituents of bear bile]. Zhongguo Zhong Yao Za Zhi 2010; 35:2416-2419.
20
21. Pal R, Rhodes E. Viscosity/concentration relationships for emulsions. J Rheol 1989; 33:1021-1045.
21
22. Silva JP, Dhall S, Garcia M, Chan A, Costa C, Gama M, et al. Improved burn wound healing by the antimicrobial peptide LLKKK18 released from conjugates with dextrin embedded in a carbopol gel. Acta Biomater 2015; 26:249-262.
22
23. Pal K, Banthia A, Majumdar D. Preparation of novel pH-sensitive hydrogels of carboxymethyl cellulose acrylates: A comparative study. Mater Manuf Process 2006; 21:877-882.
23
24. Zhang Y, Chu CC. Biodegradable dextran–polylactide hydrogel networks: Their swelling, morphology and the controlled release of indomethacin. J Biomed Mater Res 2002; 59:318-328.
24
25. Chauhan S, Nainwal N, Bisht T, Saharan V. An investigation of in-vitro release of rabeprazole sodium from pulsatile release tablet containing HPMC-EC blend as time lagged press coating. Int J Pharm Sci Res 2018; 9:2825-2831.
25
26. Mantopoulos D, Murakami Y, Comander J, Thanos A, Roh M, Miller JW, et al. Tauroursodeoxycholic acid (TUDCA) protects photoreceptors from cell death after experimental retinal detachment. PloS One 2011; 6:e24245.
26
27 Feng Y, Siu K, Wang N, Ng K-M, Tsao S-W, Nagamatsu T, et al. Bear bile: dilemma of traditional medicinal use and animal protection. J Ethnobiol Ethnomed 2009; 5:2.
27
28. Charoo NA, Kohli K, Ali A. Preparation of in situ‐forming ophthalmic gels of ciprofloxacin hydrochloride for the treatment of bacterial conjunctivitis: In vitro and in vivo studies. J Pharm Sci 2003; 92:407-413.
28
29. Varela-Garcia A, Concheiro A, Alvarez-Lorenzo C. Soluplus micelles for acyclovir ocular delivery: Formulation and cornea and sclera permeability. Int J Pharm 2018; 552:39-47.
29
30. Qin Y, Chang R, Ge S, Xiong L, Sun Q. Synergistic effect of glycerol and ionic strength on the rheological behavior of cellulose nanocrystals suspension system. Int J Biol Macromol 2017; 102:1073-1082.
30
31. Li C, Wang J, Wang Y, Gao H, Wei G, Huang Y, et al. Recent progress in drug delivery. Acta Pharm Sin B 2019;6:1145-1162.
31
32. Esposito S. “Traditional” sol-gel chemistry as a powerful tool for the preparation of supported metal and metal oxide catalysts. Materials 2019; 12:668.
32
33. Mohammad IS, Teng C, Chaurasiya B, Yin L, Wu C, He W. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer. Int J Pharm. 2019; 557:304-313.
33
ORIGINAL_ARTICLE
Carvacrol and Zataria multiflora influenced the PPARγ agonist effects on systemic inflammation and oxidative stress induced by inhaled paraquat in rat
Objective(s): The effects of PPAR-γ agonist alone and in combination with carvacrol and Zataria multiflora on inhaled paraquat (PQ) induced-systemic inflammation and oxidative stress were examined. Materials and Methods: Control group exposed to normal saline aerosol, one group exposed to 54 mg/m3 PQ aerosol and four groups exposed to PQ aerosol and treated with 5 mg/kg/day pioglitazone, pioglitazone + 200 mg/kg/day Z. multiflora extract, pioglitazone + 20 mg/kg/day carvacrol, and 0.03 mg /kg/day dexamethasone for 16 days after the end of exposure to PQ were studied. Exposure to normal saline or PQ was performed every other days for 30 min (8 times). Different variables were measured after the end of treatment period.Results: PQ exposure significantly increased serum levels of NO2, MDA and IL-6 but dexreased CAT and IFN-γ levels and IFN-γ/IL-6 ratio compared to control group (PConclusion: The effects of combination therapy of pioglitazone with Z. multiflora or carvacrol on inhaled paraquat (PQ) induced-oxidative stress and systemic inflammation were higher than the effects of pioglitazone alone. These results suggested that the effects of the extract and carvacrol may mediated through PPAR-γ receptors.
https://ijbms.mums.ac.ir/article_15596_50487255420d3242c8a880a58ffe3d08.pdf
2020-07-01
930
936
10.22038/ijbms.2020.45962.10648
Paraquat
PPAR-γ agonist
Zataria multiflora
Carvacrol
systemic inflammation
Oxidative stress
Fatemeh
Amin
ft.amin@yahoo.com
1
Department of Physiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
AUTHOR
Arghavan
Memarzia
meamara961@mums.ac.ir
2
Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Hamid Reza
Kazerani
kazerani@um.ac.ir
3
Department of Physiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
AUTHOR
Mohammad Hossein
Boskabady
boskabadymh@mums.ac.ir
4
Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Dhananjayan V, Ravichandran B. Occupational health risk of farmers exposed to pesticides in agricultural activities. Curr Opin Environ Sci Health 2018;4:31-37.
1
2. Hu X, Liang Y, Zhao H, Zhao M. Effects of AT-RvD1 on paraquat-induced acute renal injury in mice. Int Immunopharmacol 2019;67:231-238.
2
3. Dinis-Oliveira R, Duarte J, Sanchez-Navarro A, Remiao F, Bastos M, Carvalho F. Paraquat poisonings: mechanisms of lung toxicity, clinical features, and treatment. Crit Rev Toxicol 2008;38:13-71.
3
4. Buendía JA, Chavarriaga GJR, Zuluaga AF. Burden of paraquat poisoning in the department of Antioquia, Colombia. BMC Pharmacol Toxicol 2019; 20:11.
4
5. Asadi R, Afshari R. Ten-year disease burden of acute poisonings in Northeast Iran and estimations for national rates. Hum Exp Toxicol 2016; 35:747-59.
5
6. Kim Sj, Gil HW, Yang JO, Lee EY, Hong SY. The clinical features of acute kidney injury in patients with acute paraquat intoxication. Nephrol Dial Transplant 2008;24:1226-1232.
6
7. Yoon SC. Clinical outcome of paraquat poisoning. Korean J Intern Med 2009;24:93-94.
7
8. Gawarammana IB, Buckley NA. Medical management of paraquat ingestion. Br J Clin Pharmacol 2011;72:745-757.
8
9. Zhao G, Li S, Hong G, Li M, Wu B, Qiu Q, et al. The effect of resveratrol on paraquat-induced acute lung injury in mice and its mechanism. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2016;28:33-37.
9
10. Sun L, Yan PB, Zhang Y, Wei LQ, Li GQ. Effect of activated charcoal hemoperfusion on renal function in patients with paraquat poisoning. Exp Ther Med 2018;15:2688-2692.
10
11. Gawarammana IB, Buckley NA. Medical management of paraquat ingestion. British J Clin Pharmacol 2011;72:745-757.
11
12. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2011;2:236-240.
12
13. Youssef J, Badr MZ. PPARs: history and advances, Peroxisome Proliferator-Activated Receptors (PPARs). Springer 2013; 1-6.
13
14. Wang L, Waltenberger B, Pferschy-Wenzig E-M, Blunder M, Liu X, Malainer C, et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol 2014;92:73-89.
14
15. Fujiki Y, Okumoto K, Kinoshita N, Ghaedi K. Lessons from peroxisome-deficient Chinese hamster ovary (CHO) cell mutants. Biochim Biophys Acta 2006;1763:1374-1381.
15
16. Ohtera A, Miyamae Y, Yoshida K, Maejima K, Akita T, Kakizuka A, et al. Identification of a new type of covalent PPARγ agonist using a ligand-linking strategy. ACS Chem Biol 2015;10:2794-2804.
16
17. Sajed H, Sahebkar A, Iranshahi M. Zataria multiflora Boiss.(Shirazi thyme)—an ancient condiment with modern pharmaceutical uses. J Ethnopharmacol 2013;145:686-698.
17
18. Khazdair MR, Ghorani V, Alavinezhad A, Boskabady MH. Pharmacological effects of Zataria multiflora Boiss L. and its constituents focus on their anti-inflammatory, anti-oxidant, and immunomodulatory effects. Fundam Clin Pharmacol 2018;32:26-50.
18
19. Ahmadipour A, Sharififar F, Nakhaipour F, Samanian M, Karami-Mohajeri S. Hepatoprotective effect of Zataria multiflora Boisson cisplatin-induced oxidative stress in male rat. IJMS 2015;8:275.
19
20. Burleigh-Flayer H, Alarie Y. Concentration-dependent respiratory response of guinea pigs to paraquat aerosol. Arch Toxicol 1987;59:391-396.
20
21. Malekinejad H, Khoramjouy M, Hobbenaghi R, Amniattalab A. Atorvastatin attenuates the paraquat-induced pulmonary inflammation via PPARγ receptors: A new indication for atorvastatin. Pestic Biochem Phys 2014;114:79-89.
21
22. Jalali S, Boskabady MH, Rohani AH, Eidi A. The effect of carvacrol on serum cytokines and endothelin levels of ovalbumin sensitized guinea-pigs. Iran J Basic Med Sci 2013;16:615-619.
22
23. Heydari M, Mokhtari-Zaer A, Amin F, Memarzia A, Saadat S, Hosseini M, et al. The effect of Zataria multiflora hydroalcoholic extract on memory and lung changes induced by rats that inhaled paraquat. Nutr Neurosci 2019:1-14.
23
24. Alemán-Laporte J, Bandini LA, Garcia-Gomes MS, Zanatto DA, Fantoni DT, Amador Pereira MA, et al. Combination of ketamine and xylazine with opioids and acepromazine in rats: Physiological changes and their analgesic effect analysed by ultrasonic vocalization, Laboratory animals. 2019:0023677219850211.
24
25. Hakimizadeh E, Askary A, Shamsizadeh A, Rahmani M, Vazirinejad R, Ayoobi F, et al. Effect of hydro-alcoholic extract of Artemisia aucheri on castor oil-induced diarrhea in male rat. J Shahrekord Univ Med Sci 2013;15-22.
25
26. Khazdair MR, Ghorani V, Alavinezhad A, Boskabady MH. Effect of Zataria multiflora on serum cytokine levels and pulmonary function tests in sulfur mustard-induced lung disorders: A randomized double-blind clinical trial. J Ethnopharmacol 2020;248:112325-112333.
26
27. Shakeri F, Soukhtanloo M, Boskabady MH. The effect of hydro-ethanolic extract of Curcuma longa rhizome and curcumin on total and differential WBC and serum oxidant, anti-oxidant biomarkers in rat model of asthma. Iran J Basic Med Sci 2017;20:155-165.
27
28. Saadat S, Beheshti F, Askari VR, Hosseini M, Roshan NM, Boskabady MH. Aminoguanidine affects systemic and lung inflammation induced by lipopolysaccharide in rats. Respir Res 2019;20:96.
28
29. Facecchia K, Fochesato LA, Ray SD, Stohs SJ, Pandey S. Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies. J Toxicol 2011;2011:683728-683739.
29
30. Cheresh P, Kim S-J, Tulasiram S, Kamp DW. Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta 2013;1832:1028-1040.
30
31. Keeling PL, Smith LL. Relevance of NADPH depletion and mixed disulphide formation in rat lung to the mechanism of cell damage following paraquat administration. Biochem Pharmacol 1982;31:3243-3249.
31
32. Suntres ZE. Exploring the potential benefit of natural product extracts in paraquat toxicity. Fitoterapia 2018; 131: 160-167.
32
33. Meng Z, Dong Y, Gao H, Yao D, Gong Y, Meng Q, et al. The effects of ω-3 fish oil emulsion-based parenteral nutrition plus combination treatment for acute paraquat poisoning. Glob J Med Res 2019;47:600-614.
33
34. Kianmehr M, Rezaei A, Hosseini M, Khazdair MR, Rezaee R, Askari VR, et al. Immunomodulatory effect of characterized extract of Zataria multiflora on Th1, Th2 and Th17 in normal and Th2 polarization state. Food Chem Toxicol 2017;99:119-127.
34
35. Piguet PF, Collart MA, Grau GE, Sappino AP, Vassalli P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 1990;344:245.
35
36. Zou C, Hu H, Xi X, Shi Z, Wang G, Huang X. Pioglitazone protects against renal ischemia-reperfusion injury by enhancing anti-oxidant capacity. J Surg Res 2013;184:1092-1095.
36
37. Al Rouq F, El Eter E. PPAR-γ activator induces neuroprotection in hypercholesterolemic rats subjected to global cerebral ischemia/reperfusion injury: In vivo and in vitro inhibition of oxidative stress. Exp Gerontol 2014;51:1-7.
37
38. Storer PD, Xu J, Chavis J, Drew PD. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 2005;161:113-122.
38
39. McKinnon B, Bersinger NA, Mueller MD. Peroxisome proliferating activating receptor gamma–independent attenuation of interleukin 6 and interleukin 8 secretion from primary endometrial stromal cells by thiazolidinediones. Fertil Steril 2012;97:657-664.
39
40. Khazdair M, Alavinezhad A, Boskabady M. Carvacrol ameliorates haematological parameters, oxidant/anti-oxidant biomarkers and pulmonary function tests in patients with sulphur mustard-induced lung disorders: A randomized double-blind clinical trial. J Clin Pharm Ther 2018;43:664-674.
40
41. Khazdair MH, Rajabi O, Balali-Moodd M, Beheshtie F, Boskabady MH. The effect of Zataria multiflora on pulmonary function tests, hematological and oxidant/anti-oxidant parameters in sulfur mustard exposed veterans, a randomized doubled-blind clinical trial. Environ Toxicol Pharmacol 2018;58:180-188.
41
42. Khazdair MR, Boskabady MH. The effect of carvacrol on inflammatory mediators and respiratory symptoms in veterans exposed to sulfur mustard, a randomized, placebocontrolled trial. Respir Med 2019;150:21-29.
42
43. Kianmehr M, Rezaei A, Boskabady MH. Effect of carvacrol on various cytokines genes expression in splenocytes of asthmatic mice. Iran J Basic Med Sci 2016; 19: 402-410.
43
44. Boskabady MH, Mehrjardi SS, Rezaee A, Rafatpanah H, Jalali S. The impact of Zataria multiflora Boiss extract on in vitro and in vivo Th1/Th2 cytokine (IFN-γ/IL4) balance. J Ethnopharmacol 2013; 150: 1024-1031.
44
45. Hotta M1, Nakata R, Katsukawa M, Hori K, Takahashi S, Inoue H. Carvacrol, a component of thyme oil, activates PPARalpha and gamma and suppresses COX-2 expression. J Lipid Res 2010;51:132-139.
45
ORIGINAL_ARTICLE
Developing oncolytic Herpes simplex virus type 1 through UL39 knockout by CRISPR-Cas9
Objective(s): Oncolytic Herpes simplex virus type 1 (HSV-1) has emerged as a promising strategy for cancer therapy. However, development of novel oncolytic mutants has remained a major challenge owing to low efficiency of conventional genome editing methods. Recently, CRISPR-Cas9 has revolutionized genome editing.Materials and Methods: In this study, we aimed to evaluate the capability of CRISPR-Cas9 to manipulate the UL39 gene to create oncolytic HSV-1. Herein, three sgRNAs were designed against the UL39 gene and transfected into HEK-293 cell line followed by infection with HSV-1 KOS.Results: After three rounds of plaque purification, several HSV-1 mutants were identified by PCR analysis and sequencing. One of these mutations in which 55 nucleotides were deleted resulted in a frameshift mutation that in turn produced a truncated protein with only 167 amino acids from 1137 amino acids. Functional analysis in Vero and primary fibroblast cells revealed that viral replication was significantly lower and plaque size was smaller in the HSV-1 mutant compared with HSV-1 KOS. Moreover, the relative amount of viral genome present in the supernatants of infected cells (Vero and primary fibroblast cells) with HSV-1 mutant was significantly decreased compared with those of HSV-1 KOS.Conclusion: Our data revealed that targeting UL39 with CRISPR-Cas9 could develop oncolytic HSV-1.
https://ijbms.mums.ac.ir/article_15503_f2cf48ea378621d4d26a64f04c6feafa.pdf
2020-07-01
937
944
10.22038/ijbms.2020.43864.10286
CRISPR-Cas9
Herpes simplex virus type 1
Oncolytic virus
Ribonucleotide reductase
UL39
saeedeh
Ebrahimi
ebrahimisaeedeh62@gmail.com
1
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Manochehr
Makvandi
manoochehrmakvandi29@yahoo.com
2
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Samaneh
Abbasi
s_abbasi80@yahoo.com
3
Abadan Faculty of Medical Science, Abadan, Iran
AUTHOR
keyhan
Azadmanesh
azadmanesh@pasteur.ac.ir
4
Department of Virology, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Ali
Teimoori
teimooriali1982@gmail.com
5
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
LEAD_AUTHOR
1. Kaur B, Chiocca EA, Cripe TP. Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol 2012; 13:1842-1851.
1
2. Peters C, Rabkin SD. Designing herpes viruses as oncolytics. Mol Ther Oncolytics 2015; 2:15010.
2
3. Nishiyama Y. Herpes virus genes: Molecular basis of viral replication and pathogenicity. Nagoya J Med Sci 1996; 59:107-119.
3
4. Aghi M, Visted T, Depinho RA, Chiocca EA. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 2008; 27:4249-4254.
4
5. Currier MA, Gillespie RA, Sawtell NM, Mahller YY, Stroup G, Collins MH, et al. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther 2008; 16:879-885.
5
6. Sokolowski NA, Rizos H, Diefenbach RJ. Oncolytic virotherapy using herpes simplex virus: how far have we come? Oncolytic Virother 2015; 4:207-219.
6
7. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9:967-978.
7
8. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014; 346:1258096.
8
9. Ebrahimi S, Teimoori A, Khanbabaei H, Tabasi M. Harnessing CRISPR/Cas 9 System for manipulation of DNA virus genome. Rev Med Virol 2019; 29:e2009.
9
10. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014; 157:1262-1278.
10
11. Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas immune system: biology, mechanisms and applications. Biochimie 2015; 117:119-128.
11
12. Wang D, Wang XW, Peng XC, Xiang Y, Song SB, Wang YY, et al. CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research. Cancer Gene Ther 2018; 25:93-105.
12
13. Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J. CRISPR-Cas9: a new and promising player in gene therapy. J Med Genet 2015; 52:289-296.
13
14. Yuan M, Webb E, Lemoine NR, Wang Y. CRISPR-Cas9 as a powerful tool for efficient creation of oncolytic viruses. Viruses 2016; 8:72.
14
15. Bi Y, Sun L, Gao D, Ding C, Li Z, Li Y, et al. High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS Pathog 2014; 10:e1004090.
15
16. Finnen RL, Banfield BW. CRISPR/Cas9 mutagenesis of UL21 in multiple strains of herpes simplex virus reveals differential requirements for pUL21 in viral replication. Viruses 2018; 10:258.
16
17. Li J, Zeng W, Huang Y, Zhang Q, Hu P, Rabkin SD, et al. Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther 2012; 19:707-714.
17
18. Lin C, Li H, Hao M, Xiong D, Luo Y, Huang C, et al. Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing of HSV-1 virus in human cells. Sci Rep 2016; 6:34531.
18
19. Roehm PC, Shekarabi M, Wollebo HS, Bellizzi A, He L, Salkind J, et al. Inhibition of HSV-1 Replication by Gene Editing Strategy. Sci Rep 2016; 6:23146.
19
20. Suenaga T, Kohyama M, Hirayasu K, Arase H. Engineering large viral DNA genomes using the CRISPR-Cas9 system. Microbiol Immunol 2014; 58:513-522.
20
21. Brandt CR, Kintner RL, Pumfery AM, Visalli RJ, Grau DR. The herpes simplex virus ribonucleotide reductase is required for ocular virulence. J Gen Virol 1991; 72 ( Pt 9):2043-2049.
21
22. Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK, et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 1989; 173:276-283.
22
23. Vangipuram M, Ting D, Kim S, Diaz R, Schule B. Skin punch biopsy explant culture for derivation of primary human fibroblasts. J Vis Exp 2013:e3779.
23
24. Kennedy EM, Bassit LC, Mueller H, Kornepati AVR, Bogerd HP, Nie T, et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 2015; 476:196-205.
24
25. Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, et al. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids 2014; 3:e186.
25
26. Song Y, Lai L, Li Z. Large-scale genomic deletions mediated by CRISPR/Cas9 system. Oncotarget 2017; 8:5647.
26
27. Bhattacharya D, Van Meir EG. A simple genotyping method to detect small CRISPR-Cas9 induced indels by agarose gel electrophoresis. Sci Rep 2019; 9:4437.
27
28. Chen D, Tang JX, Li B, Hou L, Wang X, Kang L. CRISPR/Cas9-mediated genome editing induces exon skipping by complete or stochastic altering splicing in the migratory locust. BMC Biotechnol 2018; 18:60.
28
29. Ren Z, Li S, Wang QL, Xiang YF, Cui YX, Wang YF, et al. Effect of siRNAs on HSV-1 plaque formation and relative expression levels of RR mRNA. Virol Sin 2011; 26:40-46.
29
30. Idowu AD, Fraser-Smith EB, Poffenberger KL, Herman RC. Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo. Antiviral Res 1992; 17:145-156.
30
31. Mostafa HH, Thompson TW, Konen AJ, Haenchen SD, Hilliard JG, Macdonald SJ, et al. Herpes simplex virus 1 mutant with point mutations in UL39 is impaired for acute viral replication in mice, establishment of latency, and explant-induced reactivation. J Virol 2018; 92:e01654-01617.
31
32. Perkins D. Targeting apoptosis in neurological disease using the herpes simplex virus. J Cell Mol Med 2002; 6:341-356.
32
ORIGINAL_ARTICLE
Human Wharton’s jelly mesenchymal stem cells-derived secretome could inhibit breast cancer growth in vitro and in vivo
Objective(s): Controversial results have been reported regarding the anti-tumor properties of extracellular vesicles derived from mesenchymal stem cells (MSCs). The present study was conducted to evaluate whether secretome derived from Human Wharton’s jelly mesenchymal stem cells (hWJMSCs) may stimulate or inhibit breast cancer growth in vitro and in vivo.Materials and Methods: MTT assays was performed to determine anti-tumor effects of hWJMSCs-secretome on both MCF-7 and 4T1 tumor cells in vitro. Afterward, 4T1 breast tumors were established in different groups of Balb/C mice (12 mice/group). The tumor sizes were monitored in different treatment groups and at day 30 post-tumor inoculation (PTI), blood samples were obtained and 6 mice of each group were sacrificed for hematological and histopathological assays. The rest of the mice in each group (n=6) were left alive up to day 120 PTI to determine survival rate. Results: We found that hWJMSCs-secretome can inhibit growth of MCF-7 and 4T1 tumor cell lines in vitro. Moreover, intratumoral administration of hWJMSCs-secretome resulted in significant tumor growth inhibition and improvement of hematological indices in vivo and prolonged survival rate of tumor bearing mice. Conclusion: According to our findings, hWJMSCs-secretome could be considered a potent anti-tumor agent, however, further investigation should be done on other cancer models.
https://ijbms.mums.ac.ir/article_15496_bd774441acf2288d1a40ab7bb5b6476f.pdf
2020-07-01
945
953
10.22038/ijbms.2020.42477.10020
Breast Cancer
Growth inhibition
HWJMSCs
In vitro and in vivo
Secretome
Mansoureh
Mirabdollahi
mirabdollahim@yahoo.com
1
Applied Physiology Research Center, Cardiovascular Research Institute, Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Hojjat
Sadeghi-aliabadi
sadeghi@pharm.mui.ac.ir
2
Medicinal Chemistry Department, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Shaghayegh
Haghjooy Javanmard
sh_haghjoo@med.mui.ac.ir
3
Applied Physiology Research Center, Cardiovascular Research Institute, Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
1. Usha L, Rao G, Christopherson II K, Xu X. Mesenchymal stem cells develop tumor tropism but do not accelerate breast cancer tumorigenesis in a somatic mouse breast cancer model. PloS one 2013; 8:e67895.
1
2. Yu JM, Jun ES, Bae YC, Jung JS. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev 2008; 17:463-474.
2
3. Tabatabaei M, Mosaffa N, Ghods R, Nikoo S, Kazemnejad S, Khanmohammadi M, et al. Vaccination with human amniotic epithelial cells confer effective protection in a murine model of Colon adenocarcinoma. Int J cancer 2018; 142:1453-1466.
3
4. Yang J, Lv K, Sun J, Guan J. Anti-tumor effects of engineered mesenchymal stem cells in colon cancer model. Cancer Manag Res 2019; 11:8443-8450.
4
5. Ahn J-O, Coh Y-R, Lee H-W, Shin I-S, Kang S-K, Youn H-Y. Human adipose tissue-derived mesenchymal stem cells inhibit melanoma growth in vitro and in vivo. Anticancer Res 2015; 35:159-168.
5
6. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med 2006; 203:1235-1247.
6
7. Secchiero P, Zorzet S, Tripodo C, Corallini F, Melloni E, Caruso L, et al. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin’s lymphoma xenografts. PloS one 2010; 5:e11140.
7
8. Ayuzawa R, Doi C, Rachakatla RS, Pyle MM, Maurya DK, Troyer D, et al. Naive human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett 2009; 280:31-37.
8
9. Fatima F, Nawaz M. Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy. Chin J Cancer 2015; 34:541-553.
9
10. Rani S, Ryan AE, Griffin MD, Ritter T. Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications. Mol Ther 2015; 23:812-823.
10
11. Webber J, Yeung V, Clayton A, editors. Extracellular vesicles as modulators of the cancer microenvironment. Semin Cell Dev Biol; 201;40:27-34.
11
12. Cosenza S, Toupet K, Maumus M, Luz-Crawford P, Blanc-Brude O, Jorgensen C, et al. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics 2018; 8:1399-1410.
12
13. Wang X, Omar O, Vazirisani F, Thomsen P, Ekström K. Mesenchymal stem cell-derived exosomes have altered microRNA profiles and induce osteogenic differentiation depending on the stage of differentiation. PloS one 2018; 13:e0193059.
13
14. Yang Y, Bucan V, Baehre H, Von Der Ohe J, Otte A, Hass R. Acquisition of new tumor cell properties by MSC-derived exosomes. Int J Oncol 2015; 47:244-252.
14
15. Moore C, Kosgodage U, Lange S, Inal JM. The emerging role of exosome and microvesicle‐(EMV‐) based cancer therapeutics and immunotherapy. Int J Cancer 2017; 141:428-436.
15
16. Wang J, Zheng Y, Zhao M. Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells. Front Pharmacol 2017; 7:533-544.
16
17. Bruno S, Collino F, Deregibus MC, Grange C, Tetta C, Camussi G. Microvesicles Derived from Human bone marrow Mesenchymal Stem Cells Inhibit Tumor Growth. Stem Cells Dev 2013; 22:758-771.
17
18. Ji Y, Ma Y, Chen X, Ji X, Gao J, Zhang L, Hu J. Microvesicles released from human embryonic stem cell derived-mesenchymal stem cells inhibit proliferation of leukemia cells. Oncol Rep 2017; 38:1013-1020.
18
19. Wu S, Ju GQ, Du T, Zhu YJ, Liu GH. Microvesicles derived from human umbilical cord Wharton’s jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo. PloS one 2013; 8:e61366-e61366.
19
20. Lindoso RS, Collino F, Vieyra A. Extracellular vesicles as regulators of tumor fate: crosstalk among cancer stem cells, tumor cells and mesenchymal stem cells. Stem Cell Investig 2017; 4:75-89.
20
21. Bruno S, Collino F, Iavello A, Camussi G. Effects of mesenchymal stromal cell-derived extracellular vesicles on tumor growth. Front Immunol 2014; 5:382-387.
21
22. Wu J, Qu Z, Fei ZW, Wu JH, Jiang CP. Role of stem cell-derived exosomes in cancer. Oncol Lett 2017; 13:2855-2866.
22
23. Lu L, Liu Y, Yang S, Zhao Q, Wang X, Gong W, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006; 91:1017-1026.
23
24. Kadir EA, Sulaiman SA, Yahya NK, Othman NH. Inhibitory effects of tualang honey on experimental breast cancer in rats: a preliminary study. Asian Pac J Cancer Prev 2013; 14:2249-2254.
24
25. Roberti NE. The role of histologic grading in the prognosis of patients with carcinoma of the breast. Cancer 1997; 80:1708-1716.
25
26. Hendijani F, Javanmard SH, Rafiee L, Sadeghi-Aliabadi H. Effect of human Wharton’s jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells. Res Pharm sci 2015; 10:134-142.
26
27. Hendijani F, Javanmard SH, Sadeghi-aliabadi H. Human Wharton’s jelly mesenchymal stem cell secretome display antiproliferative effect on leukemia cell line and produce additive cytotoxic effect in combination with doxorubicin. Tissue Cell 2015; 47:229-234.
27
28. Mirabdollahi M, Haghjooyjavanmard S, Sadeghi-aliabadi H. An anticancer effect of umbilical cord-derived mesenchymal stem cell secretome on the breast cancer cell line. Cell Tissue Bank 2019; 20:423-434.
28
29. Lee H-Y, Hong I-S. Double-edged sword of mesenchymal stem cells: Cancer-promoting versus therapeutic potential. Cancer Sci 2017; 108:1939-1946.
29
30. Xu S, De Veirman K, De Becker A, Vanderkerken K, Van Riet I. Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? Leukemia 2018; 32:1500-1514.
30
31. Munson P, Shukla A. Exosomes: Potential in cancer diagnosis and therapy. Medicines (Basel) 2015; 2:310-327.
31
32. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Sigman CC. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev 1994; 3:85-98.
32
33. Bhome R, Del Vecchio F, Lee G-H, Bullock MD, Primrose JN, Sayan AE, et al. Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer. Cancer Lett 2018; 420:228-235.
33
34. Muralidharan-Chari V, Clancy JW, Sedgwick A, D’Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci 2010; 123:1603-1611.
34
35. Barrett JC. Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ Health Perspect 1993; 100:9-20.
35
36. Sánchez AM, Berra HH, Graciela Scharovsky O, Matar P, Gervasoni SI, Rozados VR. Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Ann Oncol 2004; 15:1543-1550.
36
37. Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: Toward Cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci 2017; 18:1852-1876.
37
38. da Silva Meirelles L, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009; 20:419-427.
38
39. Akinbami A, Popoola A, Adediran A, Dosunmu A, Oshinaike O, Adebola P, et al. Full blood count pattern of pre-chemotherapy breast cancer patients in Lagos, Nigeria. Caspian J Inter Med 2013; 4:574-579.
39
40. Shrivastava S, Singh N, Nigam AK, Chandel SS, Shrivastava R, Kumar S. Comparative study of hematological parameters along with effect of chemotherapy and radiotherapy in different stages of breast cancer. Inter J Res Med Sci 2017;5:311-315.
40
41. Dalton LW, Pinder SE, Elston CE, Ellis IO, Page DL, Dupont WD, et al. Histologic grading of breast cancer: Linkage of patient outcome with level of pathologist agreement. Mod Pathol 2000; 13:730-735.
41
ORIGINAL_ARTICLE
Curcumin promotes osteogenic differentiation of periodontal ligament stem cells through the PI3K/AKT/Nrf2 signaling pathway
Objective(s): The aim of this study was to investigate the effect of curcumin on the osteogenic differentiation of human periodontal ligament stem cells (hPDLSCs) and its underlying potential mechanism.Materials and Methods: The tissue explant adherence method was used to isolate hPDLSCs. Flowcytometry, Alizarin Red staining and Oil Red O staining were applied to confirm the stemness of the stem cells. CCK8 assays were used to evaluate the effect of curcumin at different concentrations on cytotoxicity, and alkaline phosphate (ALP) activity assays, ALP staining and Alizarin Red staining were used to measure the osteogenic differentiation ability. In addition, hPDLSCs were treated with LY294002 (a phosphatidylinositol-3-kinase [PI3K] inhibitor) and erythroid transcription factor NF-E2 siRNA (siNrf2), respectively in the presence of curcumin. Western blotting was applied to evaluate the protein kinase B (AKT) phosphorylation levels and the Nrf2 levels. Besides, western blotting, RT-qPCR, ALP activity assays, ALP staining and Alizarin Red staining were used to detect the potential effects of curcumin on osteogenic differentiation.Results: Curcumin at an appropriate concentration had no cytotoxicity and could promote osteogenic differentiation of the hPDLSCs. The results of western blotting and RT-qPCR revealed that the protein and mRNA levels of ALP, COL1 and RUNX2 were increased by curcumin, while the PI3K/AKT/Nrf2 signaling pathway was activated. In addition, LY294002 was added to inhibit the PI3K/AKT signaling pathway, or siNrf2 was used to block the Nrf2 pathway; then, the stimulatory effects of curcumin on osteogenic differentiation were reversed.Conclusion: Curcumin could promote the osteogenesis of hPDLSCs, and the effect is related to the PI3K/AKT/Nrf2 signaling pathway.
https://ijbms.mums.ac.ir/article_15652_7d1e7b26ee0b5a79a1f3312e4b15b38d.pdf
2020-07-01
954
960
10.22038/ijbms.2020.44070.10351
Akt
Curcumin
Nrf2
Osteogenic differentiation
Periodontal ligament
Stem cells
Yixuan
Xiong
976373040@qq.com
1
School of Stomatology, Shandong University, Jinan, China
AUTHOR
Bin
Zhao
1479008539@qq.com
2
School of Stomatology, Shandong University, Jinan, China
AUTHOR
Wenjing
Zhang
15953159813@163.com
3
School of Stomatology, Shandong University, Jinan, China
AUTHOR
Linglu
Jia
danlingjia@163.com
4
School of Stomatology, Shandong University, Jinan, China
AUTHOR
Yunpeng
Zhang
yunpeng_z@yahoo.com
5
School of Stomatology, Shandong University, Jinan, China
AUTHOR
Xin
Xu
xinxu@sdu.edu.cn
6
School of Stomatology, Shandong University, Jinan, China
LEAD_AUTHOR
1. Polimeni G, Xiropaidis AV, Wikesjo UM. Biology and principles of periodontal wound healing/regeneration. Periodontol 2000. 2006;41:30-47.
1
2. Maeda H, Tomokiyo A, Fujii S, Wada N, Akamine A. Promise of periodontal ligament stem cells in regeneration of periodontium. Stem Cell Res Ther. 2011;2:33.
2
3. Amani H, Arzaghi H, Bayandori M, Dezfuli AS, Pazoki‐Toroudi H, Shafiee A, et al. Controlling Cell Behavior through the Design of Biomaterial Surfaces: A Focus on Surface Modification Techniques. Advanced Materials Interfaces. 2019;6.
3
4. Butler MS, Robertson AA, Cooper MA. Natural product and natural product derived drugs in clinical trials. Nat Prod Rep. 2014;31:1612-1661.
4
5. Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int. 2014;2014:186864.
5
6. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991;57:1-7.
6
7. Qureshi S, Shah AH, Ageel AM. Toxicity studies on Alpinia galanga and Curcuma longa. Planta Med. 1992;58:124-127.
7
8. Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10.
8
9. Kim SJ, Son TG, Park HR, Park M, Kim MS, Kim HS, et al. Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J Biol Chem. 2008;283:14497-14505.
9
10. Kang SK, Cha SH, Jeon HG. Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev. 2006;15:165-174.
10
11. Mujoo K, Nikonoff LE, Sharin VG, Bryan NS, Kots AY, Murad F. Curcumin induces differentiation of embryonic stem cells through possible modulation of nitric oxide-cyclic GMP pathway. Protein Cell. 2012;3:535-544.
11
12. Yang MW, Wang TH, Yan PP, Chu LW, Yu J, Gao ZD, et al. Curcumin improves bone microarchitecture and enhances mineral density in APP/PS1 transgenic mice. Phytomedicine. 2011;18:205-213.
12
13. Hatefi M, Ahmadi MRH, Rahmani A, Dastjerdi MM, Asadollahi K. Effects of curcumin on bone loss and biochemical markers of bone turnover in patients with spinal cord injury. World Neurosurg. 2018;114:e785-e91.
13
14. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol. 2004;172:5940-5947.
14
15. Wang N, Wang F, Gao Y, Yin P, Pan C, Liu W, et al. Curcumin protects human adipose-derived mesenchymal stem cells against oxidative stress-induced inhibition of osteogenesis. J Pharmacol Sci. 2016;132:192-200.
15
16. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257-262.
16
17. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261-1274.
17
18. Guntur AR, Rosen CJ. The skeleton: a multi-functional complex organ: new insights into osteoblasts and their role in bone formation: the central role of PI3Kinase. J Endocrinol. 2011;211:123-130.
18
19. Ulici V, Hoenselaar KD, Agoston H, McErlain DD, Umoh J, Chakrabarti S, et al. The role of Akt1 in terminal stages of endochondral bone formation: angiogenesis and ossification. Bone. 2009;45:1133-1145.
19
20. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 2003;17:1352-1365.
20
21. Tsai KS, Kao SY, Wang CY, Wang YJ, Wang JP, Hung SC. Type I collagen promotes proliferation and osteogenesis of human mesenchymal stem cells via activation of ERK and Akt pathways. J Biomed Mater Res A. 2010;94:673-682.
21
22. Zingg JM, Hasan ST, Meydani M. Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors. 2013;39:101-121.
22
23. Yang C, Zhang X, Fan H, Liu Y. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res. 2009;1282:133-141.
23
24. Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the anti-oxidant-responsive element. Biochem J. 2003;371:887-895.
24
25. Wang L, Chen Y, Sternberg P, Cai J. Essential roles of the PI3 kinase/Akt pathway in regulating Nrf2-dependent antioxidant functions in the RPE. Invest Ophthalmol Vis Sci. 2008;49:1671-1678.
25
26. Gu Q, Cai Y, Huang C, Shi Q, Yang H. Curcumin increases rat mesenchymal stem cell osteoblast differentiation but inhibits adipocyte differentiation. Pharmacogn Mag. 2012;8:202-208.
26
27. Harris MT, Butler DL, Boivin GP, Florer JB, Schantz EJ, Wenstrup RJ. Mesenchymal stem cells used for rabbit tendon repair can form ectopic bone and express alkaline phosphatase activity in constructs. J Orthop Res. 2004;22:998-1003.
27
28. Nakai K, Kawato T, Morita T, Yamazaki Y, Tanaka H, Tonogi M, et al. Angiotensin II suppresses osteoblastic differentiation and mineralized nodule formation via AT1 receptor in ROS17/2.8 cells. Arch Med Sci. 2015;11:628-637.
28
29. Peltier J, O’Neill A, Schaffer DV. PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation. Dev Neurobiol. 2007;67:1348-1361.
29
30. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 2006;18:2262-2271.
30
31. Qiao J, Paul P, Lee S, Qiao L, Josifi E, Tiao JR, et al. PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. Biochem Biophys Res Commun. 2012;424:421-426.
31
32. Meng YB, Li X, Li ZY, Zhao J, Yuan XB, Ren Y, et al. microRNA-21 promotes osteogenic differentiation of mesenchymal stem cells by the PI3K/beta-catenin pathway. J Orthop Res. 2015;33:957-964.
32
33. Lu SY, Wang CY, Jin Y, Meng Q, Liu Q, Liu ZH, et al. The osteogenesis-promoting effects of alpha-lipoic acid against glucocorticoid-induced osteoporosis through the NOX4, NF-kappaB, JNK and PI3K/AKT pathways. Sci Rep. 2017;7:3331.
33
34. Zhang J, Liu X, Li H, Chen C, Hu B, Niu X, et al. Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signaling pathway. Stem Cell Res Ther. 2016;7:136.
34
35. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 2000;6:909-919.
35
36. Freudlsperger C, Horn D, Weissfuss S, Weichert W, Weber KJ, Saure D, et al. Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma. Int J Cancer. 2015;136:2775-2785.
36
37. Lee JM, Johnson JA. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol. 2004;37:139-143.
37
38. Park CK, Lee Y, Kim KH, Lee ZH, Joo M, Kim HH. Nrf2 is a novel regulator of bone acquisition. Bone. 2014;63:36-46.
38
39. Wu J, Li Q, Wang X, Yu S, Li L, Wu X, et al. Neuroprotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway. PLoS One. 2013;8:e59843.
39
40. Qi Z, Ci X, Huang J, Liu Q, Yu Q, Zhou J, et al. Asiatic acid enhances Nrf2 signaling to protect HepG2 cells from oxidative damage through Akt and ERK activation. Biomed Pharmacother. 2017;88:252-259.
40
41. Sim HJ, Kim JH, Kook SH, Lee SY, Lee JC. Glucose oxidase facilitates osteogenic differentiation and mineralization of embryonic stem cells through the activation of Nrf2 and ERK signal transduction pathways. Mol Cell Biochem. 2016;419:157-163.
41
42. Yoon DS, Choi Y, Lee JW. Cellular localization of NRF2 determines the self-renewal and osteogenic differentiation potential of human MSCs via the P53-SIRT1 axis. Cell Death Dis. 2016;7:e2093.
42